{
  "schema_version": "chamgap-public-evidence-check-1.0",
  "public_id": "v3116-main",
  "verdict_number": "3116",
  "title": "Vitamin C (single-ingredient oral L-ascorbic acid) × Change in symptomatic stone recurrence in adults with prior calcium-oxalate stones",
  "view_version": "1.0",
  "view_created_date": "2026-11-06",
  "criteria_version": "NGM-v3116-ORAL-C-SYMPTOMATIC-CAOX-RECURRENCE-1.0",
  "criteria_date": "2026-10-05",
  "review_date": "2026-10-05",
  "legacy_evidence_date": "2026-09-16",
  "review_scope": {
    "materials_read": "Stored Korean and English manuscripts and case-specific criteria and application records",
    "clinical_papers_directly_read": false,
    "new_clinical_search": false,
    "limitation": "No external clinical abstracts, full texts, registrations or analysis plans were newly read. Reading the stored summaries is distinguished from not having read the external original materials, and the original assessment, numerical values and unverified information are preserved. No new searches, calculations or reassessments were performed.",
    "date_meaning": "This is the date the stored materials were checked, not the date of an up-to-date clinical literature search."
  },
  "claim_context": {
    "population": "Adults with a confirmed history of calcium-oxalate stones",
    "comparator": "No added vitamin C, placebo or matched usual care (question boundary; actual eligible groups unverified)",
    "endpoint": "Symptomatic new calcium-oxalate stone recurrence; residual-stone growth and urinary markers excluded",
    "intervention": "Single-ingredient pure ascorbic acid; salts, foods and combination products excluded · Oral",
    "dose": "Unverified: no directly eligible recurrence comparison verified",
    "duration": "Treatment duration and principal follow-up time unverified; no fixed duration invented",
    "excluded_extensions": [
      "S01 mixed-stone composite of new stones/residual-stone growth and urinary pH",
      "S02/S03 short-term urinary oxalate and Tiselius index",
      "S04/S17 metabolic reports and unresolved overlap",
      "S05–S07/S10 cystine stones, metabolic markers/other treatments",
      "S08 observational association with first incident stones in the general population",
      "S09 acute stone dissolution during combined treatment",
      "S12 IV harms in the injection prescribing information",
      "S15/S16 registration leads with unverified content"
    ]
  },
  "requirements": [
    {
      "item_id": "N01",
      "question_type": "Claim and boundaries of the independent question",
      "question": "Which adults, oral intervention and recurrent-stone event does this table address?",
      "needed": "The original /ko/effect and question specifications for population, ingredient, route, event, comparison and time",
      "role": "Required",
      "role_reason": "Needed to avoid converting stone risk factors or first incident stones into symptomatic recurrence in patients with a history of stones.",
      "application_exception": "The question definition alone does not establish a recurrence direction, dose or duration as a verified effect or prescription. The absence of a subclaims field is also preserved.",
      "criterion": "Link the single question of comparative change in symptomatic new stones in adults with a calcium-oxalate stone history receiving pure single-ingredient oral L-ascorbic acid to the excluded questions.",
      "basis": "Principles for clarifying the question in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed; M03 §3.2.1; detailed population criteria are internally designed; M03 §3.2.2–3.2.3; reverse-direction labeling and adaptation for testing are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptation for each question is internally designed; M03 §3.2.4; internally defined limits on extrapolation",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Subsequent research should define symptomatic new calcium-oxalate stone recurrence as the main outcome and report imaging-only events, residual-stone growth and first incident stones separately.",
      "current_reports": [],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "The current claim concerns change in symptomatic new-stone recurrence in adults with a confirmed history of calcium-oxalate stones. The question compares added single-ingredient pure oral L-ascorbic acid with no addition, placebo or matched care. The actual dose, duration and direct comparative values are unverified.",
      "condition_status": "Met",
      "status_reason": "The original claim's identity and exclusion boundaries have been linked. Met does not mean that an eligible trial or a recurrence effect has been verified.",
      "missingness": "The current source has no subclaims field. No new subquestions or combinations of all axes were created to increase the number of independent tables.",
      "uncertainty": "The current source has no subclaims field. No new subquestions or combinations of all axes were created to increase the number of independent tables.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "The original /ko/effect and question specifications for population, ingredient, route, event, comparison and time"
    },
    {
      "item_id": "N02",
      "question_type": "Reference date and reading scope",
      "question": "What materials were actually read this time, and what are the historical access records?",
      "needed": "The retained summary's evidence cutoff, access records for each source, locations actually read in the current work and file SHA",
      "role": "Required",
      "role_reason": "Needed to avoid presenting past full-text/abstract access on 2026-09-16 as full-text reading performed this time.",
      "application_exception": "Current external access not attempted is not labeled as access failure. Past failures stated in the manuscript are retained only as historical records.",
      "criterion": "Separate reading of the current local stored summary from not having read clinical original texts, registrations and official documents this time, material by material.",
      "basis": "Principles for data collection/selection in M04 §4.5–4.6; separation of access from reading and the hyperlink contract are internally designed; M04 §4.5, §4.6.3; limits on the current data transformation follow the user-defined scope and internal design",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "For subsequent material verification, separately record material type, version, access attempts, sections actually read and the SHA of acquired files, and cross-check them against historical summaries.",
      "current_reports": [],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "The retained evidence through 2026-09-16 was transformed on 2026-10-05. The 17 Korean fields, designated structure and 17 sources/bibliographic entries were actually read in that work. Reading S01's 6-page PDF, part of S10 on p.1563 and official documents is recorded in the historical manuscript; all external materials remain unread this time.",
      "condition_status": "Met",
      "status_reason": "Current summary reading and historical access levels have been separated by material. No new searches or reading of original full texts or old separate logs were performed.",
      "missingness": "The historical source's external-byte hashes are empty. The methods HTML copies referenced here are not presented as copies of original clinical articles.",
      "uncertainty": "The historical source's external-byte hashes are empty. The methods HTML copies referenced here are not presented as copies of original clinical articles.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "The retained summary's evidence cutoff, access records for each source, locations actually read in the current work and file SHA"
    },
    {
      "item_id": "N03",
      "question_type": "Reports and study families",
      "question": "Have the 17 reports been kept from being double-counted as independent recurrence trials?",
      "needed": "A mapping of each report's source_id to study family, cohort, endpoint and repeat citations",
      "role": "Required",
      "role_reason": "Needed to avoid counting publisher, PubMed and PMC versions, reviews and related metabolic reports as separate trials.",
      "application_exception": "Retain the possible S04/S17 overlap as a single conservative cluster, without confirming that they involve the same participants.",
      "criterion": "Link the roles of the 10 retained families and S11–S16 documents without creating an unverified unique-participant total.",
      "basis": "Distinction between studies and reports in M04 §4.6.1–4.6.2; cohort/outcome linkage is an internal application; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application; M04 §4.6.1–4.6.2; adaptation for harms material is internally designed",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Create an overlap ledger that cross-checks original participant recruitment, registration, study locations and timing to verify Chai/Massey overlap and cohort reuse.",
      "current_reports": [
        "S01",
        "S02",
        "S04",
        "S08",
        "S11",
        "S17"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "The 17 sources are linked to the 10 families in the retained ledger. S04 and S17 were grouped in F04 because of possible but unresolved overlap. S08's 3 cohorts, reviews and cited material are not added as other independent recurrence trials. The count of 0 verified eligible comparisons pertains to the scope at that time.",
      "condition_status": "Met",
      "status_reason": "The distinctions among reports, families and reviews have been preserved. This is not exhaustive confirmation of the number of unique studies or participants.",
      "missingness": "Participant overlap between Chai/Massey and overlap with earlier cohort reports are unverified. The verified overall participant total is left empty.",
      "uncertainty": "Participant overlap between Chai/Massey and overlap with earlier cohort reports are unverified. The verified overall participant total is left empty.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "A mapping of each report's source_id to study family, cohort, endpoint and repeat citations"
    },
    {
      "item_id": "N04",
      "question_type": "Ingredient, formulation and route",
      "question": "Has the question's pure oral L-ascorbic acid been distinguished from other forms?",
      "needed": "Product ingredient list, L isomer, salts, single/combined ingredients and actual administration route",
      "role": "Required",
      "role_reason": "Needed to avoid importing foods, salts, combination products or injections as recurrence effects of the pure oral preparation.",
      "application_exception": "Harms from injections may be retained as a separate context, but are not transferred as effects or incidence for the single-ingredient oral preparation.",
      "criterion": "Identify the question's formulation boundary and distinguish it from verification of actual study-product eligibility.",
      "basis": "M03 §3.2.2–3.2.3; reverse-direction labeling and adaptation for testing are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M19 §19.2.2–19.2.4, M03 §3.2.3; internal application",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Subsequent comparisons should verify batch-specific ingredients, salts/isomers, added ingredients and administration routes, distinguishing them from food/injection exposures.",
      "current_reports": [
        "S12"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "The question concerns single-ingredient pure oral L-ascorbic acid. Sodium/calcium ascorbate, foods/juice, combination products and intravenous injections are excluded. This boundary does not mean that an actual eligible study product has been verified.",
      "condition_status": "Met",
      "status_reason": "The question boundaries between the pure oral preparation and other exposures have been preserved. Directly eligible product verification remains unverified under the next criterion.",
      "missingness": "The eligible product, manufacturing source, salt/isomer and batch identity have not been verified.",
      "uncertainty": "The eligible product, manufacturing source, salt/isomer and batch identity have not been verified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Product ingredient list, L isomer, salts, single/combined ingredients and actual administration route"
    },
    {
      "item_id": "N05",
      "question_type": "Actual product identity",
      "question": "Have the product, source and single-ingredient status of a directly eligible recurrence study been verified?",
      "needed": "Product, batch, manufacturing source, purity, ingredient list and original methods for a direct recurrence comparison",
      "role": "Required",
      "role_reason": "Because the name ascorbic acid alone cannot establish eligibility as a pure L single ingredient.",
      "application_exception": "Preserve nominal ingredients in indirect reports unchanged, without using them to fill gaps in the eligible product.",
      "criterion": "Use original data to verify whether the actual product in the selected direct comparison matches the question's formulation.",
      "basis": "M03 §3.2.2–3.2.3; reverse-direction labeling and adaptation for testing are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Design research linking product analysis or verifiable ingredient lists to the actual comparison groups and administration records.",
      "current_reports": [
        "S01"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "The product and manufacturing source for a directly eligible recurrence comparison are unverified. S01 also records that single-ingredient L-isomer purity, product and source could not be established.",
      "condition_status": "Unverified",
      "status_reason": "The current retained scope lacks material to verify the question's pure oral L formulation as the actual trial product.",
      "missingness": "Agreement between nominal ascorbic acid and the actual single ingredient, isomer and manufacturing source is unverified.",
      "uncertainty": "Agreement between nominal ascorbic acid and the actual single ingredient, isomer and manufacturing source is unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Product, batch, manufacturing source, purity, ingredient list and original methods for a direct recurrence comparison"
    },
    {
      "item_id": "N06",
      "question_type": "Population and stone history",
      "question": "Is this direct evidence about adults with a confirmed history of calcium-oxalate stones?",
      "needed": "Age, prior stone diagnosis/composition, recurrence history, baseline status and inclusion/exclusion table",
      "role": "Required",
      "role_reason": "Needed to avoid recasting general-population, cystine-stone or mixed-stone groups as adults with a calcium-oxalate stone history.",
      "application_exception": "The question's editorial boundary of adulthood at age 18 is not transferred as the actual minimum age in each study.",
      "criterion": "Verify the actual population's age, prior stone composition and diagnosis, and whether it matches the question's population.",
      "basis": "M03 §3.2.1; detailed population criteria are internally designed; M19 §19.1.2–19.2.4; detailed distinctions are internally designed",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Analyze prior stone composition and verify history before recruitment, reporting data for adults with a calcium-oxalate stone history separately from other compositions.",
      "current_reports": [
        "S01",
        "S02"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "The question's population is adults with a confirmed history of calcium-oxalate stones. S01 concerns alkaline urine and mixed stones, while S02 is a short-term metabolic study in calcium-oxalate stone formers. Comparative symptomatic-recurrence values matching this population have not been verified.",
      "condition_status": "Unverified",
      "status_reason": "Although related human data exist, a direct result meeting the population, endpoint and comparison criteria together remains unverified.",
      "missingness": "The age boundary, number/timing of prior episodes, composition verification and baseline risk for an actual eligible comparison are unknown.",
      "uncertainty": "The age boundary, number/timing of prior episodes, composition verification and baseline risk for an actual eligible comparison are unknown.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Age, prior stone diagnosis/composition, recurrence history, baseline status and inclusion/exclusion table"
    },
    {
      "item_id": "N07",
      "question_type": "S01 selection and composition denominators",
      "question": "How are S01's 43 identified, 24 included and 17 composition-verified participants distinguished?",
      "needed": "Patient selection flow, age, sex, stone-composition testing table and reasons for exclusion",
      "role": "Required",
      "role_reason": "Needed to avoid using the total identified population, included group and composition-tested group as the same recurrence-analysis denominator.",
      "application_exception": "A calcium-oxalate cell of 0 in the follow-up composition table is not interpreted as 0 calcium-oxalate recurrences among all 24 participants.",
      "criterion": "Link S01's recruited, included, composition-verified and event groups separately within the original reporting scope.",
      "basis": "M03 §3.2.1; detailed population criteria are internally designed; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations by design are internally designed; M19 §19.1.2–19.2.4; internal application",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Subsequent research should disclose participant-level flow and missing tests from recruitment through composition testing and event adjudication.",
      "current_reports": [
        "S01"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "S01 identified 43 patients and included 24. Mean age was 60.6 years (95% CI 52.7–68.5), and 11/24 were women. Among the 17 with baseline composition verified, 9 had struvite, 6 carbonate apatite and 2 calcium oxalate. Among the 3 with follow-up composition verified, 2 had struvite and 1 carbonate apatite; the calcium-oxalate cell of 0 does not provide a denominator establishing 0 recurrences.",
      "condition_status": "Partly verified",
      "status_reason": "The retained selection and composition counts can be distinguished, but the analysis of symptomatic recurrence confined to calcium-oxalate stones and the details of missingness and selection are unverified.",
      "missingness": "The minimum adult age, reasons for inclusion and exclusion, missing composition testing, and comparator-specific event results confined to calcium-oxalate stones are unverified.",
      "uncertainty": "The minimum adult age, reasons for inclusion and exclusion, missing composition testing, and comparator-specific event results confined to calcium-oxalate stones are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Patient selection flow, age, sex, stone-composition testing table and reasons for exclusion"
    },
    {
      "item_id": "N08",
      "question_type": "S01 composite events",
      "question": "What outcome and follow-up period do the 8/24 events in S01 represent?",
      "needed": "Event tables by new-stone and residual-stone-growth component, symptom status, composition, and median or fixed follow-up information",
      "role": "Required",
      "role_reason": "This is needed to avoid presenting a mixed composite event as a symptomatic calcium-oxalate recurrence rate or a causal effect.",
      "application_exception": "Preserve the fact that urinary pH was the original study's main endpoint and stone events were a secondary endpoint. Do not turn pH or oxalate P values into recurrence P values.",
      "criterion": "Attribute 8/24, 33.3%, and the median follow-up of 22.6 months only to the original composite outcome.",
      "basis": "M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations were internally designed; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations were internally designed; M03 §3.2.4; internally defined limits on extension; M19 §19.1.2–19.2.4; detailed distinctions were internally designed",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Comparative studies are needed that adjudicate new stones, growth of existing stones, and symptomatic events separately, and distinguish prespecified fixed-time outcomes from time to first recurrence.",
      "current_reports": [
        "S01"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "In S01, a composite event of new stones or growth/progression of existing stones was observed in 8/24 participants (33.3%). Median follow-up was 22.6 months (range 19.7–32.1 months), and the original main endpoint was urinary pH. This value is neither a symptomatic recurrence rate confined to calcium-oxalate stones nor a causal effect of vitamin C.",
      "condition_status": "Partly verified",
      "status_reason": "The composite events and follow-up summary are retained, but a direct comparative result for the target event cannot be separately verified.",
      "missingness": "Counts by new-stone/growth component, symptoms, recurrence by composition, a fixed time point, and a comparison with no addition are unverified.",
      "uncertainty": "Counts by new-stone/growth component, symptoms, recurrence by composition, a fixed time point, and a comparison with no addition are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Event tables by new-stone and residual-stone-growth component, symptom status, composition, and median or fixed follow-up information"
    },
    {
      "item_id": "N09",
      "question_type": "S01 nominal exposure",
      "question": "Is the dose in S01 a regimen from a directly eligible trial?",
      "needed": "Nominal daily dose, product, dose per administration/frequency, meal timing, actual intake, and administration records",
      "role": "Required",
      "role_reason": "This is needed to avoid using a dose from an indirect report involving mixed stone types as an established regimen for the target population.",
      "application_exception": "Do not turn the median of 1000 mg/day and range of 500–2000 mg/day into an individual recommendation or a direct dose comparison.",
      "criterion": "Distinguish the verified nominal dose in S01 from the unverified product, frequency, and duration of intake.",
      "basis": "M03 §3.2.2–3.2.3; reverse-direction labeling and adaptation for testing were internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M03 §3.2.1–3.2.4; details concerning dose, duration, and effect modification were internally designed",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Obtain the product and daily and per-administration dosing records, adherence, and changes in exposure by group to compare nominal dose with actual exposure.",
      "current_reports": [
        "S01"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "The median daily dose of ascorbic acid in S01 was 1000 mg/day (range 500–2000 mg/day). The product, L-form purity, administration frequency, meal timing, and sustained adherence are unverified. These values were not used to fill in a dose for a directly eligible recurrence study or an individual prescription.",
      "condition_status": "Partly verified",
      "status_reason": "Only the nominal daily dose from an indirect report is verified; there is no directly eligible exposure information.",
      "missingness": "The actual eligible product, dose per administration/frequency, meal timing, treatment duration, medication adherence, and comparative effects by dose are unverified.",
      "uncertainty": "The actual eligible product, dose per administration/frequency, meal timing, treatment duration, medication adherence, and comparative effects by dose are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Nominal daily dose, product, dose per administration/frequency, meal timing, actual intake, and administration records"
    },
    {
      "item_id": "N10",
      "question_type": "Direct comparator",
      "question": "Has a recurrence comparator involving no addition, placebo, or the same care been verified?",
      "needed": "Comparators, care, concomitant interventions, event counts, and correspondence with the exposure group in the same population",
      "role": "Required",
      "role_reason": "This is needed to avoid mistaking events observed in an exposure group for a between-group increase or decrease in risk.",
      "application_exception": "The metabolic placebo condition in S02 and the healthy participants in S03 do not replace a comparator for the recurrence question.",
      "criterion": "Link the actual comparator for the target event and the effect of interest to the original result.",
      "basis": "M03 §3.2.2–3.2.3; reverse-direction labeling and adaptation for testing were internally designed; M08 §8.1–8.2.3; internal application; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M19 §19.2.2–19.2.4, M03 §3.2.3; internal application",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Compare an added single-ingredient oral preparation with no addition/placebo on top of the same usual care, and record events by group together with differences in care.",
      "current_reports": [
        "S01",
        "S02",
        "S03"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "No addition, placebo, and the same usual care are the comparator question in this table. S01 has no unexposed recurrence comparator, and the placebo in S02 is a short-term metabolic comparison. A directly eligible recurrence comparator is unverified.",
      "condition_status": "Unverified",
      "status_reason": "There is no retained result that verifies the question's comparator as an actually observed eligible group.",
      "missingness": "Exposure by group, common treatment, baseline risk, and recurrence numerators and denominators are unverified.",
      "uncertainty": "Exposure by group, common treatment, baseline risk, and recurrence numerators and denominators are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Comparators, care, concomitant interventions, event counts, and correspondence with the exposure group in the same population"
    },
    {
      "item_id": "N11",
      "question_type": "Duration and principal follow-up time",
      "question": "Have the treatment duration and principal follow-up time for comparing recurrence been verified?",
      "needed": "Actual treatment start/end, discontinuation, follow-up/censoring, and prespecified principal follow-up time",
      "role": "Required",
      "role_reason": "This is needed to avoid turning median follow-up or 3/6-day metabolic exposure into a fixed clinical recurrence period.",
      "application_exception": "Do not create a common minimum duration. Do not round a median of 22.6 months into a fixed 24-month result.",
      "criterion": "Distinguish the treatment duration, fixed time point, and time-to-event analysis of a directly eligible comparison within the verified scope.",
      "basis": "M03 §3.2.2–3.2.3; reverse-direction labeling and adaptation for testing were internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations were internally designed; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations were internally designed; M03 §3.2.1–3.2.4; details concerning dose, duration, and effect modification were internally designed; design-specific harms questions in M19 §19.2; details of temporal relationships were internally designed",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Prespecify a defensible principal time point considering event accumulation and discontinuation/censoring, and report treatment duration separately from follow-up duration.",
      "current_reports": [
        "S01",
        "S02",
        "S03"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "The treatment duration and principal follow-up time of a directly eligible recurrence comparison are unverified. The 22.6 months in S01 is median follow-up, not a fixed 24-month endpoint. The 6 days per period in S02 and the 3 days in S03 are metabolic exposure periods.",
      "condition_status": "Unverified",
      "status_reason": "There are no direct comparative data with which to establish the principal recurrence time point and exposure duration.",
      "missingness": "Eligible treatment duration, cumulative exposure, recurrence after discontinuation, fixed follow-up, and person-years/censoring information are unverified.",
      "uncertainty": "Eligible treatment duration, cumulative exposure, recurrence after discontinuation, fixed follow-up, and person-years/censoring information are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Actual treatment start/end, discontinuation, follow-up/censoring, and prespecified principal follow-up time"
    },
    {
      "item_id": "N12",
      "question_type": "Event definition and measurement",
      "question": "Can symptomatic new stones be distinguished from imaging-only events and residual-stone growth?",
      "needed": "Symptoms, imaging/diagnosis, stone composition, adjudicators, definitions of new and residual stones, and event collection procedures",
      "role": "Required",
      "role_reason": "This is needed to avoid combining different clinical and imaging events as the same recurrence outcome.",
      "application_exception": "Emergency care, procedures, and time to first recurrence are separate outcomes and are not all added together as a single event.",
      "criterion": "Link the definition, diagnosis, and adjudication of the target event and its distinction from other events to the direct result.",
      "basis": "M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations were internally designed; M08 Table 8.2.a, M03 §3.2.4; internal application; M03 §3.2.4; internally defined limits on extension; M19 §19.1.2–19.2.4; detailed distinctions were internally designed",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Apply event adjudication with group information masked where possible and standardized procedures for verifying symptoms, imaging, and composition.",
      "current_reports": [
        "S01"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "The question's endpoint is symptomatic new calcium-oxalate stone recurrence. The manuscript does not combine new stones/residual-stone growth, imaging-only events, emergency care/procedures, and time to first recurrence. A separate result meeting this target definition was not verified within the composite events in S01.",
      "condition_status": "Unverified",
      "status_reason": "The question's definition is fixed, but the target event actually measured and adjudicated in a directly eligible comparison is unverified.",
      "missingness": "Symptom adjudication, composition verification, assessor masking, differences in detection during follow-up, and overlap between event categories are unverified.",
      "uncertainty": "Symptom adjudication, composition verification, assessor masking, differences in detection during follow-up, and overlap between event categories are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Symptoms, imaging/diagnosis, stone composition, adjudicators, definitions of new and residual stones, and event collection procedures"
    },
    {
      "item_id": "N13",
      "question_type": "Direct effect and uncertainty",
      "question": "Have an effect estimate, CI, and P value for an eligible recurrence comparison been verified?",
      "needed": "Events/denominators and time by group, original risk ratio/risk difference/HR, CI, P value, and analysis definition",
      "role": "Required",
      "role_reason": "This is needed to avoid filling in a recurrence comparison effect with indirect proportions, metabolic-measure P values, or first-stone HRs.",
      "application_exception": "Preserve unverified values as empty values and do not make new calculations from rounded proportions or other outcomes.",
      "criterion": "Attribute the estimate, direction, measure, and interval of a directly eligible comparison to its event and time point.",
      "basis": "M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations were internally designed; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations were internally designed; M08 §8.2.2, M15 §15.3.1; internal application; M15 §15.3.1–15.3.3; internal application; M19 §19.2.2–19.2.4, M03 §3.2.3; internal application; M19 §19.1.2–19.2.4; internal application",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Report relative and absolute effects and intervals for prespecified symptomatic recurrence using the same analysis population and a fixed time point or a time-to-event model.",
      "current_reports": [],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "In the original primary_result, source_id, estimate, CI, P, and n are all empty values, and the direction is unknown. Numerators/denominators, risk ratios/risk differences/hazard ratios/HRs, person-years, and censoring for eligible recurrence are also unverified. S01 8/24, S02 P<0.001, and the S08 HR were not transferred into these empty fields.",
      "condition_status": "Unverified",
      "status_reason": "A directly eligible comparative estimate cannot be verified within the retained material currently read. This does not mean an effect of 0.",
      "missingness": "The original estimate, interval, denominator, time, and effect of interest for the target event are unverified.",
      "uncertainty": "The original estimate, interval, denominator, time, and effect of interest for the target event are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Events/denominators and time by group, original risk ratio/risk difference/HR, CI, P value, and analysis definition"
    },
    {
      "item_id": "N14",
      "question_type": "Design, allocation, and confounding",
      "question": "Have an actual design and allocation that support a causal comparison of recurrence been verified?",
      "needed": "Direct comparison methods, allocation/concealment, baseline risk, observational-study confounding/selection, and models",
      "role": "Required",
      "role_reason": "This is needed to avoid claiming that a causal comparison of the target recurrence has been resolved merely because a related study is labeled an RCT.",
      "application_exception": "Retain metabolic crossover trials and observational reports while distinguishing them from designs addressing the target event.",
      "criterion": "Verify actual design, allocation, and confounding information for the target outcome, and distinguish the axes that must remain unverified.",
      "basis": "M08 §8.1–8.2.3; internal application; M08 §8.2.2, M15 §15.3.1; internal application; design considerations in M19 §19.2.2–19.2.4; detailed confounding records were internally designed",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Prespecify a randomized comparison on top of the same usual care or an appropriate comparative design that explicitly addresses confounding and selection pathways.",
      "current_reports": [
        "S01",
        "S02",
        "S08"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "S01 is a retrospective report of an exposure group alone, S02 is a randomized double-blind metabolic crossover trial, and S08 is an observational analysis of first stones. Allocation, concealment, and baseline balance in a direct recurrence comparison were not verified.",
      "condition_status": "Unverified",
      "status_reason": "The actual existence of other designs does not establish a causal comparison for the target clinical event.",
      "missingness": "Allocation, concealment, design, confounding adjustment, and baseline balance in a direct recurrence comparison are unknown.",
      "uncertainty": "Allocation, concealment, design, confounding adjustment, and baseline balance in a direct recurrence comparison are unknown.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Direct comparison methods, allocation/concealment, baseline risk, observational-study confounding/selection, and models"
    },
    {
      "item_id": "N15",
      "question_type": "Concomitant interventions, adherence, and contribution",
      "question": "Can common treatments, deviations from medication use, and concomitant interventions be separated from vitamin C's contribution?",
      "needed": "Fluid intake/diet, medications/procedures, rescue treatment, adherence, exposure changes, and their handling in analysis by group",
      "role": "Required",
      "role_reason": "This is needed to avoid attributing the results of concomitant treatments or exposure changes to the contribution of a single-ingredient oral preparation.",
      "application_exception": "Do not assume that there were no concurrent changes. The acute course with antibiotics/stenting in S09 is not an effect on recurrence prevention.",
      "criterion": "Distinguish actual concomitant interventions and deviations from exposure needed to define the effect of interest from the unverified scope.",
      "basis": "M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M08 §8.2.2, M15 §15.3.1; internal application; design considerations in M19 §19.2.2–19.2.4; detailed confounding records were internally designed",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Collect fluid intake, diet, concurrent medications/procedures, rescue treatments, and actual medication use/discontinuation by group, and analyze them in accordance with the prespecified effect of interest.",
      "current_reports": [
        "S01",
        "S09"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "In S01, sustained adherence, product, and frequency are unverified, and discontinuation/dose reduction related to hyperoxaluria is recorded. The acute dissolution in S09 is a case combining concurrent exposure to antibiotics and stenting with different exposure after discharge. The effects of concomitant interventions and deviations in a direct comparison are unverified.",
      "condition_status": "Unverified",
      "status_reason": "There is no eligible recurrence analysis that separates common care and exposure changes by group.",
      "missingness": "Fluid intake, diet, medications/procedures, medication adherence, changes by group, and ITT/adherence effects are unverified.",
      "uncertainty": "Fluid intake, diet, medications/procedures, medication adherence, changes by group, and ITT/adherence effects are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Fluid intake/diet, medications/procedures, rescue treatment, adherence, exposure changes, and their handling in analysis by group"
    },
    {
      "item_id": "N16",
      "question_type": "Denominators and events/people",
      "question": "Have recurrence events, people, exposure time, and analysis denominators been verified?",
      "needed": "Numbers allocated/exposed, completing follow-up, and analyzed; recurrent events/people with events; follow-up time; and censoring tables",
      "role": "Required",
      "role_reason": "This is needed to avoid confusing data in which a person experiences multiple events with proportions of people or incidence rates.",
      "application_exception": "Do not turn the 8/24 count of people with composite events into an eligible incidence rate or a denominator specific to calcium-oxalate recurrence.",
      "criterion": "Verify the analysis denominator, event unit, time, and interval of the direct result together.",
      "basis": "M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations were internally designed; M19 §19.1.2–19.2.4; internal application; M08 §8.2.2, M15 §15.3.1; internal application",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Separate people with events from recurrent events using participant IDs and a time axis, and disclose denominators and censoring for first-recurrence and recurrent-event analyses.",
      "current_reports": [
        "S01",
        "S05"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "The 8/24 in S01 is the reported value for composite events in the exposure group. Numerators/denominators by group, event counts/person counts, person-years, and censoring for directly eligible recurrence were not verified. The 2 people with spontaneous passage or populations with other stone compositions are not added to a new-recurrence numerator.",
      "condition_status": "Unverified",
      "status_reason": "The target event unit and the comparative analysis denominator are not verified within the currently retained scope.",
      "missingness": "Units for first/recurrent events, follow-up time, analysis n by group, and censoring are unverified.",
      "uncertainty": "Units for first/recurrent events, follow-up time, analysis n by group, and censoring are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Numbers allocated/exposed, completing follow-up, and analyzed; recurrent events/people with events; follow-up time; and censoring tables"
    },
    {
      "item_id": "N17",
      "question_type": "Missing data, selection, and censoring",
      "question": "Who was included, lost to follow-up, or censored, and how was the target outcome handled?",
      "needed": "Participant flow, missing outcomes, censoring, reasons for exclusion, and analysis/sensitivity-analysis plans",
      "role": "Required",
      "role_reason": "This is needed to avoid extending observations limited to the included exposure group to the entire recruited population or presenting them as results without missing data.",
      "application_exception": "Do not present unverified full texts or flow diagrams as evidence of no missing data or a definite magnitude of bias.",
      "criterion": "Distinguish actual participant flow from missingness/censoring of the target recurrence, and explicitly identify unverified handling.",
      "basis": "M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations were internally designed; M08 §8.2.2, M15 §15.3.1; internal application; M19 §19.1.2–19.2.4, M04 §4.6.3; internal application",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Disclose losses to follow-up, missing event ascertainment, and reasons for censoring by group, and perform prespecified sensitivity analyses for missing data.",
      "current_reports": [
        "S01"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "The 43 people identified and 24 included in S01 are retained, but missingness, censoring, and their handling for the target recurrence by group are unverified. Because an actually eligible comparison has not been verified, these values cannot be designated as an ITT denominator.",
      "condition_status": "Unverified",
      "status_reason": "The retained inclusion flow alone cannot establish the impact of missingness/censoring on the target comparison.",
      "missingness": "The recruitment→exposure→follow-up→analysis flow, reasons for missingness, and sensitivity analyses by group are unverified.",
      "uncertainty": "The recruitment→exposure→follow-up→analysis flow, reasons for missingness, and sensitivity analyses by group are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Participant flow, missing outcomes, censoring, reasons for exclusion, and analysis/sensitivity-analysis plans"
    },
    {
      "item_id": "N18",
      "question_type": "Differences in detection and adjudication",
      "question": "Were symptom assessment, imaging, and event adjudication conducted under the same conditions across groups?",
      "needed": "Examination schedules, symptom collection, imaging/composition testing, masking/adjudicators, and detection/reporting pathways",
      "role": "Required",
      "role_reason": "This is needed to avoid mistaking imaging findings in a more frequently examined group for an actual difference in symptomatic recurrence.",
      "application_exception": "Do not mark masking or equivalent detection as met merely because imaging data are objective.",
      "criterion": "Explain the collection, adjudication, and detection conditions for the direct target event and what remains unverified.",
      "basis": "M08 Table 8.2.a, M03 §3.2.4; internal application; M19 §19.1.2–19.2.4; detailed distinctions were internally designed; M19 §19.1.2–19.2.4, M04 §4.6.3; internal application",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Apply the same follow-up/symptom contacts and prespecified event adjudication procedures across groups, and disclose examination frequency together with missing adjudication.",
      "current_reports": [
        "S01"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "The retained manuscript distinguishes symptomatic new stones, imaging-only findings, growth, and urinary measures. Whether the same examination schedule, assessor masking, and event adjudication were applied in a direct comparison is unverified.",
      "condition_status": "Unverified",
      "status_reason": "There are no direct data with which to compare the actual collection and measurement procedures for the target recurrence.",
      "missingness": "Imaging frequency, symptom contacts, diagnostic/composition adjudication, and missingness by group are unverified.",
      "uncertainty": "Imaging frequency, symptom contacts, diagnostic/composition adjudication, and missingness by group are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Examination schedules, symptom collection, imaging/composition testing, masking/adjudicators, and detection/reporting pathways"
    },
    {
      "item_id": "N19",
      "question_type": "Precision and important differences",
      "question": "Can the reported interval and a clinically important difference in recurrence be interpreted?",
      "needed": "Direct recurrence effect, CI, events/denominators, and a justified criterion for an important difference",
      "role": "Required",
      "role_reason": "This is needed to avoid declaring recurrence evidence sufficient on the basis of publication count, sample size, or statistical significance alone.",
      "application_exception": "Do not create uniform minimum participant counts, minimum durations, or numerical thresholds for important differences. Do not calculate an absent CI from indirect reports.",
      "criterion": "Record the relationship between the interval for the selected event and the importance criterion, or the reason this remains unverified.",
      "basis": "M15 §15.3.1–15.3.3; internal application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations were internally designed",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Prespecify a difference in recurrence justified from clinical and patient perspectives, and report the effect interval and basis for precision for that event and follow-up.",
      "current_reports": [],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "The CI and effect estimate for eligible recurrence are unverified (the historical manuscript's explanation of CX/EX). A sample of 24 participants or a large sample in another cohort was not treated as sufficient precision for recurrence. An important difference and an appropriate minimum duration are also undetermined.",
      "condition_status": "Unverified",
      "status_reason": "Without a direct interval and a justified criterion for clinical importance, their relationship to evidence sufficiency cannot be assessed.",
      "missingness": "The eligible CI, variance/event count, important difference, and design basis for precision are unverified.",
      "uncertainty": "The eligible CI, variance/event count, important difference, and design basis for precision are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Direct recurrence effect, CI, events/denominators, and a justified criterion for an important difference"
    },
    {
      "item_id": "N20",
      "question_type": "Planning, registration, and reporting",
      "question": "Have prespecified recurrence endpoints, the principal time point, and analyses been compared with actual reporting?",
      "needed": "Registration, protocol, analysis plan, amendment history, and actual results tables for the direct trial",
      "role": "Required",
      "role_reason": "This is needed to avoid turning unavailable planning materials into a definite conclusion of nonregistration or selective reporting.",
      "application_exception": "Do not use a registration shell or a mirror lead as an actually eligible recurrence protocol.",
      "criterion": "Explain prespecification status and the parts not compared at each relevant location.",
      "basis": "M08 Table 8.2.a, M04 §4.6.3; internal application; M04 §4.5, §4.6.3; limits on the current data transformation reflect the user-defined scope and internal design",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Disclose the recurrence event definition, principal time point, comparator, analysis/interval, missing-data handling, and reasons for changes in advance, and compare them with the final results.",
      "current_reports": [
        "S01",
        "S15"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "Registration, protocol, and analysis plan for directly eligible recurrence are unverified. Preserve urinary pH as the original main endpoint and stones as a secondary endpoint in S01; unverified registration does not establish whether selective reporting occurred. Historical access to the official S15 record reached only a shell.",
      "condition_status": "Unverified",
      "status_reason": "The current scope contains no records with which to compare planned and actual endpoints and analyses for the target comparison.",
      "missingness": "The timing of prospective registration, original protocol, principal time point, analysis changes, and consistency with results are unverified.",
      "uncertainty": "The timing of prospective registration, original protocol, principal time point, analysis changes, and consistency with results are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Registration, protocol, analysis plan, amendment history, and actual results tables for the direct trial"
    },
    {
      "item_id": "N21",
      "question_type": "Short-term crossover and urinary outcomes",
      "question": "Which population, exposure, and comparison does the crossover metabolic result in S02 describe?",
      "needed": "Original S02 methods/results tables, population, duration, sample, crossover contrast, and urinary oxalate units",
      "role": "Supplementary; required for attributing indirect results",
      "role_reason": "This is needed to retain controlled short-term urinary results while distinguishing them from clinical recurrence outcomes.",
      "application_exception": "Do not turn urinary oxalate or the authors' description of a 33% increase into a probability of symptomatic recurrence.",
      "criterion": "Distinguish the actual roles of the 12 calcium-oxalate stone formers and 12 nonformers, 6-day periods, 1 g twice daily, 41.0/30.5 mg, and P.",
      "basis": "M03 §3.2.1; detailed population criteria were internally designed; M03 §3.2.2–3.2.3; reverse-direction labeling and adaptation for testing were internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations were internally designed; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations were internally designed; M08 §8.1–8.2.3; internal application; M03 §3.2.4; internally defined limits on extension",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "For metabolic crossover trials, disclose the original paired comparison, diet, and sequence; assess the clinical recurrence question through separate long-term event follow-up and comparisons.",
      "current_reports": [
        "S02"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "S02 compared ascorbic acid 1 g twice daily with a matching placebo during two 6-day controlled-diet periods in 12 calcium-oxalate stone formers and 12 nonformers. Testing during the final 2 days of each period reported urinary oxalate of 41.0 mg versus 30.5 mg in stone formers, P < 0.001. The authors' description of a 33% increase is preserved as originally reported and was not recalculated. This is not a recurrence event result.",
      "condition_status": "Partly verified",
      "status_reason": "The metabolic crossover result is included in the current extraction, but it does not answer an eligible symptomatic recurrence comparison.",
      "missingness": "Direct recurrence events and long-term follow-up are unverified. Detailed methods within the unread full-text scope also remain a separate gap.",
      "uncertainty": "Direct recurrence events and long-term follow-up are unverified. Detailed methods within the unread full-text scope also remain a separate gap.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Original S02 methods/results tables, population, duration, sample, crossover contrast, and urinary oxalate units"
    },
    {
      "item_id": "N22",
      "question_type": "Crossover sequence and paired uncertainty",
      "question": "Have the sequence, washout period, paired variance, and carryover effects in S02 been verified?",
      "needed": "S02 full text, allocation sequence, washout period, results by period, paired variance, and carryover/deviation analyses",
      "role": "Supplementary; required for interpreting crossover results",
      "role_reason": "This is needed to avoid calculating a parallel-group CI or a clinical event difference from crossover sample sizes and means alone.",
      "application_exception": "Do not fill unavailable methods with assumptions of no washout, definite carryover, or paired variance of 0.",
      "criterion": "State the boundary between the currently verified crossover design and the unverified sequence and paired uncertainty.",
      "basis": "M08 §8.1–8.2.3; internal application; M08 §8.2.2, M15 §15.3.1; internal application; M15 §15.3.1–15.3.3; internal application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations were internally designed",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Report participant-level period contrasts, period/sequence, carryover effects, and missingness from the original crossover data according to the prespecified plan, and disclose the necessary paired uncertainty.",
      "current_reports": [
        "S02"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "S02 was indexed as a randomized double-blind crossover trial, but detailed values for washout, sequence, paired variance, product, and adverse events were not verified in the abstract accessed. The two populations of 12 participants each were not treated as a 24-participant parallel-group comparison of recurrence, and no new CI was calculated for the urinary outcome.",
      "condition_status": "Unverified",
      "status_reason": "The current abstract extraction alone cannot verify paired uncertainty between crossover periods or the handling of carryover and sequence.",
      "missingness": "Washout, crossover sequence, paired variance, original analysis, product, and adverse-event counts are unverified.",
      "uncertainty": "Washout, crossover sequence, paired variance, original analysis, product, and adverse-event counts are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "S02 full text, allocation sequence, washout period, results by period, paired variance, and carryover/deviation analyses"
    },
    {
      "item_id": "N23",
      "question_type": "Short-term before–after and healthy-participant comparison",
      "question": "What was compared in the before–after metabolic study S03?",
      "needed": "Original S03 methods/results, stone composition, exposure/testing by group, the role of healthy participants, and paired data",
      "role": "Supplementary; required for interpreting indirect data",
      "role_reason": "This is needed to avoid using healthy participants as recurrence comparators for people with prior stones or extending before–after changes into an effect of adding treatment.",
      "application_exception": "The description 'calcium stone formers' alone does not establish that everyone had a verified history of calcium-oxalate recurrence.",
      "criterion": "Preserve the role of the 3-day urinary measures for the groups of 23/24 among the 47 stone formers and for the 20 healthy participants, and separate them from the target event.",
      "basis": "M03 §3.2.1; detailed population criteria were internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations were internally designed; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations were internally designed; M08 §8.2.2, M15 §15.3.1; internal application; M03 §3.2.4; internally defined limits on extension",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Disclose paired comparisons, composition, and diet/exposure for short-term metabolic data; study recurrence in adults with verified prior stones using a separate comparator receiving the same care.",
      "current_reports": [
        "S03"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "S03 provides before–after data from 47 adult calcium stone formers, of whom 23 received 1 g/day and 24 received 2 g/day for 3 days, plus data from 20 healthy participants receiving 1 g/day. It addresses urinary oxalate, pH, and the Tiselius crystallization index, not a long-term recurrence comparison. The healthy participants are not recurrence comparators for patients with prior stones, and the stone-former population was not verified as consisting entirely of calcium-oxalate stones.",
      "condition_status": "Partly verified",
      "status_reason": "The population and short-term metabolic role are retained, but the population, event, and comparison for the target recurrence are not verified.",
      "missingness": "The exact formulation, paired uncertainty, adverse events, and symptomatic recurrence comparisons by composition are unverified.",
      "uncertainty": "The exact formulation, paired uncertainty, adverse events, and symptomatic recurrence comparisons by composition are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Original S03 methods/results, stone composition, exposure/testing by group, the role of healthy participants, and paired data"
    },
    {
      "item_id": "N24",
      "question_type": "Bibliography and unresolved duplication",
      "question": "Have detailed results and participant overlap between S04 and S17 been verified?",
      "needed": "Full texts of both original reports, populations/recruitment, study IDs, participant overlap, and original results tables",
      "role": "Supplementary; required for interpreting duplication and existence",
      "role_reason": "This is needed to avoid counting the existence of metadata as acquisition of actual results or as two independent replications.",
      "application_exception": "A conservative single cluster is not a conclusion proving that the participants were the same. Leave unverified DOI/PMID information as it is.",
      "criterion": "Separate the titles/bibliographic information actually read from unverified methods, numbers, and duplication, and do not sum participants or trials.",
      "basis": "The distinction between studies and reports in M04 §4.6.1–4.6.2; cohort/outcome linkage is an internal application; data collection/selection principles in M04 §4.5–4.6; the separation of access and reading and the hyperlink contract were internally designed; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Compare recruitment periods, institutions, participants, and designs in the two original reports to verify whether they belong to the same family, and update only the scope for which results have actually been acquired.",
      "current_reports": [
        "S04",
        "S17"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "For S04 Massey 2005 and S17 Chai 2004, only indexed titles/bibliographic information from the original publications is retained; detailed results, samples, and doses are not verified in this work. Participant overlap remains unresolved, so they remain in a conservative single cluster, F04. The DOI/PMID for S17 are empty values, and the two papers were not added as independent replications.",
      "condition_status": "Unverified",
      "status_reason": "Because detailed original results and the overlap relationship have not been acquired, actual replication or recurrence results cannot be verified.",
      "missingness": "Original full texts, detailed N/dose/results, funding, and participant overlap between Chai/Massey are unverified.",
      "uncertainty": "Original full texts, detailed N/dose/results, funding, and participant overlap between Chai/Massey are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Full texts of both original reports, populations/recruitment, study IDs, participant overlap, and original results tables"
    },
    {
      "item_id": "N25",
      "question_type": "Cystine recurrence and passage",
      "question": "How are the cystine course and spontaneous passage in S05 distinguished?",
      "needed": "S05 German full text, composition, ages, event definitions, exposure/time, comparators, and complete participant flow",
      "role": "Supplementary; required for interpreting unfavorable results and scope",
      "role_reason": "This is needed to retain contrary or unfavorable human results without mixing other stone compositions and events into the target recurrence.",
      "application_exception": "Do not add the 2 people with spontaneous passage to new-recurrence events or turn the 17 participants into a denominator for adult calcium-oxalate recurrence.",
      "criterion": "Preserve the respective roles of the 17 participants, 5 g/day, 5 people with unchanged recurrence, 2 people with spontaneous passage, and the limitations concerning pediatric indexing and duration.",
      "basis": "M03 §3.2.1; detailed population criteria were internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations were internally designed; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations were internally designed; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application; M19 §19.1.2–19.2.4; internal application",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "For cystine data, separately verify composition, age, recurrence versus passage, concomitant interventions/exposure, and follow-up in the original report, and analyze them separately from calcium-oxalate studies.",
      "current_reports": [
        "S05"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "The translated abstract of S05 reports that, among 17 people with cystine stones receiving 5 g/day, recurrence remained unchanged in 5 people and another strategy was needed. The 2 people with spontaneous passage are not a recurrence numerator. Children are also indexed, and the adult-only denominator, duration, and matched comparator are unverified. This shows that human event data exist, but it is not a direct calcium-oxalate comparison.",
      "condition_status": "Partly verified",
      "status_reason": "The unfavorable event description is retained, but composition, age, comparator, and event definition differ from the target question or are unverified.",
      "missingness": "The adult-only denominator, follow-up duration, recurrence definition, concomitant interventions, identity of a pure single-ingredient preparation, and comparator are unverified.",
      "uncertainty": "The adult-only denominator, follow-up duration, recurrence definition, concomitant interventions, identity of a pure single-ingredient preparation, and comparator are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "S05 German full text, composition, ages, event definitions, exposure/time, comparators, and complete participant flow"
    },
    {
      "item_id": "N26",
      "question_type": "Favorable small report",
      "question": "To what extent has the favorable report of 4 people in S06 been verified?",
      "needed": "S06 full text, exact ages, exposure/product, events, denominators, comparison, follow-up, and concomitant interventions",
      "role": "Supplementary; required for retaining positive evidence",
      "role_reason": "This is needed to retain a favorable report without filling in unavailable conditions as evidence of target efficacy.",
      "application_exception": "Do not treat the description 'young patients with cystinuria' as equivalent to adults with prior calcium-oxalate stones.",
      "criterion": "Record both the existence of the favorable description involving 4 people and the unverified detailed eligibility and original numerical values.",
      "basis": "M03 §3.2.1; detailed population criteria were internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; the separation of statuses was internally designed; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Verify the identity, ages, composition, exposure, events/time, and comparator in the original small report, then attribute the result only to the scope of the corresponding question.",
      "current_reports": [
        "S06"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "S06 retains a description from an indexed abstract excerpt that ascorbic acid monotherapy was favorable in 4 young patients with cystinuria. Exact ages, doses, event denominators, comparators, and follow-up in the original full text are unverified. The existence of a favorable result is not erased, and it is not promoted to recurrence efficacy for this question.",
      "condition_status": "Partly verified",
      "status_reason": "A favorable small-scale description exists, but eligibility regarding composition, age, events, exposure, and comparison is not verified.",
      "missingness": "The full text, adult eligibility, dose/duration, event denominators, comparators, follow-up, and concomitant interventions are unverified.",
      "uncertainty": "The full text, adult eligibility, dose/duration, event denominators, comparators, follow-up, and concomitant interventions are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "S06 full text, exact ages, exposure/product, events, denominators, comparison, follow-up, and concomitant interventions"
    },
    {
      "item_id": "N27",
      "question_type": "Urinary cystine and publication timing",
      "question": "Have the favorable urinary result in S07 and the original report date been distinguished?",
      "needed": "Original 1982 S07 report, clinical events/follow-up, composition, exposure, and publication/digital identity",
      "role": "Supplementary; required for interpreting indirect evidence and identity",
      "role_reason": "This is needed to avoid transferring improvements in urinary measures to improved recurrence or counting a digital date as a new study.",
      "application_exception": "Do not turn the description of urinary cystine and sediment in 31 people into a controlled clinical recurrence result.",
      "criterion": "Distinguish the original 1982 report from the digitization date, and distinguish the scope of the 31 participants, 5 g/day, and urinary outcomes.",
      "basis": "The distinction between studies and reports in M04 §4.6.1–4.6.2; cohort/outcome linkage is an internal application; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations were internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; the separation of statuses was internally designed; M03 §3.2.4; internally defined limits on extension",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Compare the original publication identity with the actual patient data, and verify cystine urinary measures and clinical recurrence as separate outcomes and follow-up.",
      "current_reports": [
        "S07"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "The original publisher abstract for S07 records 31 people with cystinuria, 5 g/day, and favorable urinary cystine results. Controlled longitudinal recurrence is not verified. The later digitization date does not indicate a new study in 2010; the original report dates to 1982.",
      "condition_status": "Partly verified",
      "status_reason": "The favorable urinary description and original publication identity are retained, but this is not a clinical recurrence comparison for the target composition.",
      "missingness": "The original clinical event definition, comparison, follow-up, and adult calcium-oxalate eligibility are unverified.",
      "uncertainty": "The original clinical event definition, comparison, follow-up, and adult calcium-oxalate eligibility are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Original 1982 S07 report, clinical events/follow-up, composition, exposure, and publication/digital identity"
    },
    {
      "item_id": "N28",
      "question_type": "First occurrence and observational association",
      "question": "How does the first-stone cohort result in S08 differ from the recurrence question?",
      "needed": "Original S08 population/history, sex, exposure, covariates, events/time, HR/CI, and records of cohort reuse",
      "role": "Supplementary; required for interpreting observational and indirect results",
      "role_reason": "This is needed to avoid transferring a first-occurrence association in a large observational sample to a causal effect on recurrence in people with prior stones.",
      "application_exception": "Do not create a combined effect or denominator that erases sex differences, unverified formulations, or cohort reuse.",
      "criterion": "Preserve the actual roles of the 156,735 women, 40,536 men, 6,245 events, median 11.3–11.7 years, and the supplement contrast in men.",
      "basis": "M03 §3.2.1; detailed population criteria were internally designed; M03 §3.2.2–3.2.3; reverse-direction labeling and adaptation for testing were internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations were internally designed; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations were internally designed; M08 §8.2.2, M15 §15.3.1; internal application; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application; M19 §19.2.2–19.2.4, M03 §3.2.3; internal application; design considerations in M19 §19.2.2–19.2.4; detailed confounding records were internally designed",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Verify exclusions based on stone history, exposure/formulation, covariates, events/follow-up by sex, and reuse of the original cohorts; study the causal recurrence question through a separate comparison in a population with prior stones.",
      "current_reports": [
        "S08"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "S08 is an observational analysis reporting 6,245 first stones among 156,735 women and 40,536 men, with median follow-up of 11.3–11.7 years. For supplemental vitamin C ≥ 1,000 mg/day versus no supplementation in men, the adjusted HR was 1.19 (95% CI 1.01–1.40), with a trend P = 0.001; the abstract did not report an association in women. Distinguish dietary C, supplements, and sex, and do not use the first-occurrence association as a causal effect on recurrence in people with prior calcium-oxalate stones.",
      "condition_status": "Partly verified",
      "status_reason": "The first-occurrence association and reported values from the large cohorts are retained, but the population, event, and design differ from a direct recurrence comparison.",
      "missingness": "The original full text, exact supplemental formulation, detailed history-based exclusions/recurrence subgroups, covariates, and overlap are unverified.",
      "uncertainty": "The original full text, exact supplemental formulation, detailed history-based exclusions/recurrence subgroups, covariates, and overlap are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Original S08 population/history, sex, exposure, covariates, events/time, HR/CI, and records of cohort reuse"
    },
    {
      "item_id": "N29",
      "question_type": "Acute dissolution and concomitant-treatment case report",
      "question": "To which interventions and event is the acute dissolution course in S09 attributable?",
      "needed": "Original S09 case report, exact title/bibliographic information, stone composition, concurrent/subsequent exposure, and acute/recurrence follow-up",
      "role": "Supplementary; required for attributing case-report findings",
      "role_reason": "This is needed to avoid attributing the course involving antibiotics, stenting, and acidification in a single case to recurrence prevention by a single-ingredient oral preparation.",
      "application_exception": "Do not present a descriptive title as the exact title of the original article or turn inferred composition into confirmed composition.",
      "criterion": "Preserve the acute course with concomitant treatments in 1 older man, different exposure after discharge, uncertainty about composition, and the title's status.",
      "basis": "M03 §3.2.1; detailed population criteria were internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations were internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; design considerations in M19 §19.2.2–19.2.4; detailed confounding records were internally designed",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Separately verify the exposure timeline, concomitant interventions, composition confirmation, and acute dissolution versus long-term recurrence in the original case report, and assess the isolated contribution through an appropriate separate comparison.",
      "current_reports": [
        "S09"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "S09 describes the acute dissolution course in 1 older man, with antibiotics, stenting, and ascorbic acid used concurrently and different exposure after discharge. Stone composition was inferred, and these are not controlled recurrence data. The retained title is a descriptive label, not a transcription of the exact original title.",
      "condition_status": "Partly verified",
      "status_reason": "The case's course and limitations are retained, but it is not a comparison that isolates the recurrence effect of a single ingredient.",
      "missingness": "The exact original title, composition confirmation, contributions of individual concomitant interventions, long-term comparative recurrence, and full text are unverified.",
      "uncertainty": "The exact original title, composition confirmation, contributions of individual concomitant interventions, long-term comparative recurrence, and full text are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Original S09 case report, exact title/bibliographic information, stone composition, concurrent/subsequent exposure, and acute/recurrence follow-up"
    },
    {
      "item_id": "N30",
      "question_type": "Partial page and other treatments",
      "question": "Have the page actually verified in S10 and recurrence under other treatments been distinguished?",
      "needed": "Original S10 full text, populations/compositions by treatment, exposure, comparison/recurrence, and cited original reports",
      "role": "Supplementary; required for partial-reading status and attribution",
      "role_reason": "This is needed to avoid presenting a discussion of cystine treatment on a single page as verification of the entire full text or as a recurrence comparison of C alone.",
      "application_exception": "Do not count cited studies as new patients or assign recurrence values from other treatments to vitamin C.",
      "criterion": "Preserve partial verification of the abstract and p.1563 and the unverified comparison of C alone.",
      "basis": "The distinction between studies and reports in M04 §4.6.1–4.6.2; cohort/outcome linkage is an internal application; data collection/selection principles in M04 §4.5–4.6; the separation of access and reading and the hyperlink contract were internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations were internally designed; M03 §3.2.4; internally defined limits on extension",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Compare original exposures, denominators, and recurrence by treatment and the cited families, and clearly record the page/full-text scope actually verified.",
      "current_reports": [
        "S10"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "S10 discusses several treatments for cystinuria; the original abstract and a single page, p.1563, were historically verified. This is not recorded as reading the entire article's full text. A controlled recurrence result for vitamin C alone was not verified, and results from other treatments or cited articles are not transferred to C-alone results.",
      "condition_status": "Partly verified",
      "status_reason": "The role of the partial original page is linked, but this is not verification of the target recurrence result for the single ingredient alone.",
      "missingness": "The complete methods/results, the comparison and events/denominators for C alone, and details of the cited families are unverified.",
      "uncertainty": "The complete methods/results, the comparison and events/denominators for C alone, and details of the cited families are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Original S10 full text, populations/compositions by treatment, exposure, comparison/recurrence, and cited original reports"
    },
    {
      "item_id": "N31",
      "question_type": "Review and search timing",
      "question": "What evidence map and time frame does the S11 review provide?",
      "needed": "S11 review full text, search end date/scope, original reference list, inclusion/exclusion, and funding",
      "role": "Supplementary; required for interpreting the review and timing",
      "role_reason": "This is needed to avoid counting the review as an independent new trial or as completion of a current exhaustive search.",
      "application_exception": "Even though the online publication on 2026-07-31 preceded the evidence cutoff date, it does not mean that all studies have currently been verified.",
      "criterion": "Preserve the review's map of urinary risks, the roles of the original trials, and the limitations of access and search scope.",
      "basis": "The distinction between studies and reports in M04 §4.6.1–4.6.2; cohort/outcome linkage is an internal application; M04 §4.5, §4.6.3; limits on the current data transformation reflect the user-defined scope and internal design; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Compare the review's search end date and inclusion scope with the identities of the original reports, and update the observations in the corresponding row only when a new direct comparison has actually been acquired.",
      "current_reports": [
        "S11"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "S11 is an online review dated 2026-07-31, preceding the evidence cutoff date of 2026-09-16. Its abstract/reference list was used as an evidence map of urinary-risk studies; it is not a new recurrence trial. A review with an earlier search end date does not establish that the current search is exhaustive, nor does it provide replication independent in funding.",
      "condition_status": "Partly verified",
      "status_reason": "The review's mapping and timing roles are retained, but these are neither direct recurrence results nor current exhaustive acquisition.",
      "missingness": "The review full text, complete search scope, recent omissions, and eligibility/funding of the original references are unverified.",
      "uncertainty": "The review full text, complete search scope, recent omissions, and eligibility/funding of the original references are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "S11 review full text, search end date/scope, original reference list, inclusion/exclusion, and funding"
    },
    {
      "item_id": "N32",
      "question_type": "Registration shell and mirror identity",
      "question": "Have the registration leads in S15 and S16 been distinguished from the content actually verified?",
      "needed": "Complete official S15 registration/amendment history, original official S16 ID/version, protocols, and results",
      "role": "Supplementary; required for registration identity",
      "role_reason": "This is needed to avoid turning an official record shell and a 3rd-party mirror lead into an eligible completed trial or a negative search.",
      "application_exception": "Do not assume that NCT06989320 and the Carbon-13 oral-loading mirror are the same trial.",
      "criterion": "Record access failures involving the official shell, the mirror's status as a discovery lead, and the unverified ID at their respective locations.",
      "basis": "Data collection/selection principles in M04 §4.5–4.6; the separation of access and reading and the hyperlink contract were internally designed; M04 §4.5, §4.6.3; limits on the current data transformation reflect the user-defined scope and internal design; M08 Table 8.2.a, M04 §4.6.3; internal application",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Verify each lead's official identity, original version, population/exposure, recurrence endpoint, and result availability, and link them only after actually checking whether they are the same study.",
      "current_reports": [
        "S15",
        "S16"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "For S15 NCT06989320, only the official registration shell was historically accessed; substantive fields, registration timing, and results are unverified. S16 Carbon-13 Ascorbic Acid oral loading is a discovery lead from a 3rd-party mirror, and the official ID/version is unverified. They are not linked as the same trial, and lack of access is not turned into a completed negative search or absence of recurrence trials.",
      "condition_status": "Unverified",
      "status_reason": "The substantive original registrations/protocols/results and the identities of the two leads could not be verified.",
      "missingness": "Official IDs, versions, registration timing, eligible populations/exposures, results, and the identity relationship are unverified.",
      "uncertainty": "Official IDs, versions, registration timing, eligible populations/exposures, results, and the identity relationship are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Complete official S15 registration/amendment history, original official S16 ID/version, protocols, and results"
    },
    {
      "item_id": "N33",
      "question_type": "Contrary results and differences between records",
      "question": "Are favorable/unfavorable results and bibliographic differences being mistaken for conflicts about the same effect?",
      "needed": "Actual contrasts, events/compositions, durations, bibliographic versions, and contrary/corrected material for each original report",
      "role": "Supplementary; required for interpreting contrary evidence and conflicts",
      "role_reason": "This is needed to avoid selectively retaining only favorable evidence or turning different outcomes into a statistical conflict about the same effect.",
      "application_exception": "If the other exact value underlying the publication-identity difference in S01 is unavailable, do not invent a new year or a correction event.",
      "criterion": "Distinguish the direct and indirect roles of unfavorable/favorable results from differences between records and unverified information.",
      "basis": "M04 §4.6.3, M15 §15.3.1–15.3.3; the separation of statuses was internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations were internally designed; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Compare original populations, ingredients, contrasts, time points, and outcomes/versions to establish whether a conflict concerns the same question/analysis, and verify bibliographic corrections against original evidence.",
      "current_reports": [
        "S01",
        "S05",
        "S06",
        "S07",
        "S08"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "Favorable cystine urinary results and small-scale clinical courses are retained alongside unchanged recurrence, hyperoxaluria, and first-occurrence associations. Different compositions, endpoints, and designs are not turned into statistical conflicts about the same recurrence effect. For S01, a historical bibliographic difference is recorded in which the original PDF's 2017 publication identity took precedence, but the exact value on the other page and whether a correction occurred are currently unverified.",
      "condition_status": "Partly verified",
      "status_reason": "Indirect evidence in the contrary direction and bibliographic differences are retained, but a conflict concerning the same directly eligible effect is not verified.",
      "missingness": "Contrary/unpublished results for the same recurrence contrast, the exact value on the other S01 bibliographic page, and any original correction are unverified.",
      "uncertainty": "Contrary/unpublished results for the same recurrence contrast, the exact value on the other S01 bibliographic page, and any original correction are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Actual contrasts, events/compositions, durations, bibliographic versions, and contrary/corrected material for each original report"
    },
    {
      "item_id": "N34",
      "question_type": "Funding, provision, and independence",
      "question": "Have funding, product provision, roles, and conflicts of interest for the direct evidence been verified?",
      "needed": "Funding/conflicts of interest, internal support, product provision, and design/analysis/publication roles in original eligible reports",
      "role": "Required",
      "role_reason": "This is needed to avoid turning unverified information into absence of support or conflicts of interest, or into independent replication.",
      "application_exception": "The delivery package's default I1 designation is not an empirically verified finding of mixed funding. Do not create an independence score without eligible evidence.",
      "criterion": "Distinguish declarations actually read from unverified information, ineligible roles, and historical designations.",
      "basis": "Chamgap's own independence and attribution criteria. The official methods sections used in this pilot do not substantiate every detail of this item.",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Verify funding, product provision, and actual design/analysis/publication roles for the original eligible comparison, and separately disclose unverified items and the independence of linked families.",
      "current_reports": [
        "S01",
        "S02",
        "S05",
        "S08"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "Because there is no directly eligible recurrence evidence, the current independence axis is an empty value. Funding records in each evidence entry and historical access to the declaration section of S01 are retained. The package's I1 is a trace of a delivery default and is not used as verification of actual mixed funding or as a new independence score.",
      "condition_status": "Unverified",
      "status_reason": "Funding/provision and roles for directly eligible evidence could not be verified, and the package designation alone cannot support an assessment.",
      "missingness": "Funding, internal support, product provision, research roles, and independence of linked families for an eligible comparison are unverified.",
      "uncertainty": "Funding, internal support, product provision, research roles, and independence of linked families for an eligible comparison are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Funding/conflicts of interest, internal support, product provision, and design/analysis/publication roles in original eligible reports"
    },
    {
      "item_id": "N35",
      "question_type": "Hyperoxaluria and exposure changes",
      "question": "Have safety events in S01 been distinguished from comparative risk?",
      "needed": "S01 event definitions, exposure time, original flow of 2 people/24 people, comparator, dose reduction/discontinuation, and safety follow-up",
      "role": "Supplementary; required for interpreting harm signals",
      "role_reason": "This is needed to retain observed exposure changes without mistaking them for causal risk estimates or the proportion with any adverse event.",
      "application_exception": "Do not turn the 2 people with hyperoxaluria-related changes into 2 clinical new-stone events or a between-group risk difference.",
      "criterion": "Preserve the 1 discontinuation and 1 dose reduction, the noncomparative/mixed population, and the limitations concerning exposure duration.",
      "basis": "M19 §19.1.2–19.2.4; detailed distinctions were internally designed; design-specific harms questions in M19 §19.2; details of temporal relationships were internally designed; M19 §19.2.2–19.2.4, M03 §3.2.3; internal application; M19 §19.1.2–19.2.4; internal application; M19 §19.1.2–19.2.4; internal application",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Collect hyperoxaluria/clinical harms and discontinuations/dose reductions by group under the same formulation, exposure-time, and testing criteria, and disclose events together with exposed participant counts and time.",
      "current_reports": [
        "S01"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "S01 records hyperoxaluria-related exposure changes in 2 of 24 people (1 discontinuation and 1 dose reduction). This is a retained safety signal, not a recurrence numerator from the same report or a risk estimate by comparator. Event definitions, risk by exposure time, and complete collection of other adverse events are unverified.",
      "condition_status": "Partly verified",
      "status_reason": "Exposure changes are present in the verifiable extraction, but direct comparative risk and comprehensive harm surveillance are not verified.",
      "missingness": "The comparator, equivalent testing/exposure time, distinction of clinical harms, and denominators for all adverse events/discontinuations are unverified.",
      "uncertainty": "The comparator, equivalent testing/exposure time, distinction of clinical harms, and denominators for all adverse events/discontinuations are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "S01 event definitions, exposure time, original flow of 2 people/24 people, comparator, dose reduction/discontinuation, and safety follow-up"
    },
    {
      "item_id": "N36",
      "question_type": "High-dose gastritis and age",
      "question": "Which population, dose, and duration does the report of gastritis-related discontinuation in S05 concern?",
      "needed": "S05 gastritis definition, flow of 3 people/17 people, adults/children, 5 g/day, duration, and other treatments/risks",
      "role": "Supplementary; required for retaining unfavorable harm findings",
      "role_reason": "This is needed to avoid omitting a safety report from a high-dose population with another stone type or transferring it to comparative risk in the target adults.",
      "application_exception": "Do not calculate the 3 discontinuations as a risk rate over a defined period in adults with calcium-oxalate stones.",
      "criterion": "Retain the 17 people with cystine stones, 5 g/day, and 3 gastritis-related discontinuations together with unverified age/duration and comparator information.",
      "basis": "M19 §19.1.2–19.2.4; detailed distinctions were internally designed; M19 §19.1.2–19.2.4; internal application; M19 §19.1.2–19.2.4; internal application; M19 §19.1.2–19.2.4; internal application",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Verify original ages, definitions of gastritis/discontinuation, exposure time, concurrent treatments, and events/denominators; study harms for the target formulation/population through separate comparative surveillance.",
      "current_reports": [
        "S05"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "The translated abstract of S05 records 3 gastritis-related treatment discontinuations among 17 people with cystine stones receiving 5 g/day. Pediatric indexing is included, and the adult-only denominator, duration, and comparator are unverified. This is not used as a comparative risk rate in the target adult calcium-oxalate population.",
      "condition_status": "Partly verified",
      "status_reason": "The unfavorable discontinuation report is retained, but directness regarding population, time, and comparator is not verified.",
      "missingness": "The adult analysis denominator, gastritis definition, exposure time, comparator, concomitant interventions, and completeness of event collection are unverified.",
      "uncertainty": "The adult analysis denominator, gastritis definition, exposure time, comparator, concomitant interventions, and completeness of event collection are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "S05 gastritis definition, flow of 3 people/17 people, adults/children, 5 g/day, duration, and other treatments/risks"
    },
    {
      "item_id": "N37",
      "question_type": "Intravenous label and limits of applicability",
      "question": "Have the warnings in the official injection label S12 been separated from oral evidence?",
      "needed": "Route/formulation, warnings, and at-risk populations in the original ASCOR label, and actual comparative data on oral harms",
      "role": "Supplementary; required for interpreting harms by route",
      "role_reason": "This is needed to preserve official warnings without transferring risk frequencies or efficacy from another route to this oral preparation.",
      "application_exception": "Warnings for a buffered intravenous scurvy preparation are neither event rates nor assurances of safety for a pure oral preparation.",
      "criterion": "Distinguish intravenous oxalate nephropathy/stones, renal function/dialysis/prior history, and the high-dose/intravenous G6PD context.",
      "basis": "M03 §3.2.2–3.2.3; reverse-direction labeling and adaptation for testing were internally designed; M19 §19.1.2–19.2.4; internal application; Chamgap's own interpretive boundary. M19 principles are referenced; no formal causality tool was applied; M19 §19.1.2–19.2.4; internal application",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Verify route, formulation, at-risk populations, and event definitions in the official label, and study renal/hemolytic harms of the target oral exposure through separate exposure-specific comparisons and surveillance.",
      "current_reports": [
        "S12"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "The S12 ASCOR injection label records warnings concerning intravenous oxalate nephropathy/stones, impaired renal function, dialysis, and prior oxalate stones. G6PD-related hemolysis belongs to the high-dose/intravenous context. This is a buffered intravenous preparation for short-term treatment of scurvy, distinct from a pure oral supplement, so intravenous event rates or safety are not transferred to oral use.",
      "condition_status": "Partly verified",
      "status_reason": "The routes and populations of the historical official warnings are retained, but they do not constitute a quantitative comparison of the target oral risk.",
      "missingness": "Renal and hemolytic events, comparator denominators, and special-population risks for the target oral formulation and dose/time are unverified.",
      "uncertainty": "Renal and hemolytic events, comparator denominators, and special-population risks for the target oral formulation and dose/time are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Route/formulation, warnings, and at-risk populations in the original ASCOR label, and actual comparative data on oral harms"
    },
    {
      "item_id": "N38",
      "question_type": "General upper limit, gastrointestinal effects, and iron",
      "question": "Have the general upper limit and harms in S13 been distinguished from an assurance of safety for stone patients?",
      "needed": "Upper limit/population and gastrointestinal/iron warnings in the NIH consumer material, and actual exposure-specific safety data in the target patients",
      "role": "Supplementary; required for interpreting upper limits and general harms",
      "role_reason": "This is needed to avoid mistaking the general adult upper limit for a safe prescribed dose or a no-harm threshold in stone patients.",
      "application_exception": "Do not represent reading the full consumer document as reading the health-professional page. Intake below the upper limit does not assure stone safety.",
      "criterion": "Preserve the total of 2,000 mg/day from all sources and the context of diarrhea/nausea/abdominal pain and iron overload.",
      "basis": "M19 §19.1.2–19.2.4; internal application; Chamgap's own interpretive boundary. M19 principles are referenced; no formal causality tool was applied; M19 §19.1.2–19.2.4; internal application",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Separately verify total dietary/supplemental exposure, stone history, and iron metabolism/symptoms, and assess patient-specific safety questions through actual exposure- and population-specific comparisons/surveillance.",
      "current_reports": [
        "S13"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "S13 records diarrhea, nausea, and abdominal pain from the NIH consumer document, together with the context of high-dose iron overload in hemochromatosis. The adult upper limit of 2,000 mg/day is a general limit for the total from all sources, not an assurance of safety for stone patients. The consumer document was historically read; this is distinguished from the failed access to the health-professional page.",
      "condition_status": "Partly verified",
      "status_reason": "General official information is retained, but it does not verify comparative safety or a prescription for the target patients/exposure.",
      "missingness": "Quantitative harms by stone history, total exposure, and iron metabolism, and specific safety data in pregnancy/lactation and children are unverified.",
      "uncertainty": "Quantitative harms by stone history, total exposure, and iron metabolism, and specific safety data in pregnancy/lactation and children are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Upper limit/population and gastrointestinal/iron warnings in the NIH consumer material, and actual exposure-specific safety data in the target patients"
    },
    {
      "item_id": "N39",
      "question_type": "Guideline caution and quantitative results",
      "question": "What outcome does the guidance to avoid excessive intake in S14 verify?",
      "needed": "Original EAU section, population, evidence/warnings, and actual comparative recurrence/harm data for the target oral formulation",
      "role": "Supplementary; required for interpreting guidelines",
      "role_reason": "This is needed to avoid turning guideline caution into a randomized recurrence effect or an individual safety assessment.",
      "application_exception": "Do not create a new threshold dose or a quantitative reduction in recurrence from statements about disputed risk and avoidance of excessive intake.",
      "criterion": "Preserve the context of advice to calcium-oxalate stone formers to avoid excessive intake and the unverified quantitative direct recurrence result.",
      "basis": "M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations were internally designed; Chamgap's own interpretive boundary. M19 principles are referenced; no formal causality tool was applied; M19 §19.1.2–19.2.4; internal application",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Compare the original evidence cited by the guideline, formulation/population, and dose context, and assess quantitative recurrence/harm questions using actual comparative data.",
      "current_reports": [
        "S14"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "The S14 EAU section advises calcium-oxalate stone formers to avoid excessive vitamin C and explains that stone risk is controversial. This provides context for caution; it does not provide a randomized quantitative recurrence effect or a safety threshold dose for a pure single-ingredient oral preparation.",
      "condition_status": "Partly verified",
      "status_reason": "Guideline caution is linked, but it is neither a quantitative comparison of the target recurrence/harms nor a safe prescription.",
      "missingness": "Direct comparative recurrence/harms and a justified safety threshold dose for the target formulation, dose, and duration are unverified.",
      "uncertainty": "Direct comparative recurrence/harms and a justified safety threshold dose for the target formulation, dose, and duration are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Original EAU section, population, evidence/warnings, and actual comparative recurrence/harm data for the target oral formulation"
    },
    {
      "item_id": "N40",
      "question_type": "Special populations and long-term gaps",
      "question": "Have gaps concerning renal risk, special populations, and long-term exposure been retained?",
      "needed": "Formulation- and route-specific data on renal risks, dialysis, prior oxalate stones/G6PD, iron, pregnancy/lactation, children, and long-term harms",
      "role": "Supplementary; required for limits on safety applicability",
      "role_reason": "This is needed to avoid treating populations with weak evidence or long-term high-dose exposure as safe on the basis of the general adult upper limit or data from other routes.",
      "application_exception": "This table is not an individual diagnosis, prescription, or safety assessment, and reported doses are not turned into recommended doses.",
      "criterion": "State the current caution, unverified information by population, route, and duration, and the separation of efficacy and safety.",
      "basis": "M19 §19.1.2–19.2.4; internal application; Chamgap's own interpretive boundary. M19 principles are referenced; no formal causality tool was applied; M03 §3.2.1–3.2.4; details concerning dose, duration, and effect modification were internally designed; M19 §19.1.2–19.2.4; internal application",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "Prespecify special populations, independently monitor total exposure/duration, renal function/hemolysis/iron, and gastrointestinal/stone events, and disclose adequate follow-up and denominators.",
      "current_reports": [
        "S01",
        "S05",
        "S12",
        "S13",
        "S14"
      ],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "The current safety designation is Caution. Uncertainties concerning impaired renal function, dialysis, oxalate nephropathy, high-dose/intravenous G6PD, iron overload, pregnancy, lactation, children, and long-term high-dose exposure are retained separately. Historical reports of 500–2,000 mg/day or 5 g/day are not used as safe prescriptions for the target patients.",
      "condition_status": "Unverified",
      "status_reason": "The current scope contains no data that verify comparative harms of the target oral preparation in special populations or over the long term.",
      "missingness": "Comparative harms by population/route, total exposure, and duration, and safety in pregnancy/lactation, children, and long-term exposure are unverified.",
      "uncertainty": "Comparative harms by population/route, total exposure, and duration, and safety in pregnancy/lactation, children, and long-term exposure are unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Formulation- and route-specific data on renal risks, dialysis, prior oxalate stones/G6PD, iron, pregnancy/lactation, children, and long-term harms"
    },
    {
      "item_id": "N41",
      "question_type": "Preservation of the original assessment and calculations",
      "question": "Have the current assessment and package/calculator designations been distinguished with their original values preserved?",
      "needed": "Original records of current grade/score, axes, primary_result, historical package/calculations, and editorial decisions",
      "role": "Required for preservation and traceability; not a condition establishing efficacy",
      "role_reason": "This is needed to avoid mistaking table production or a structural PASS for confirmation of a clinical grade or effect.",
      "application_exception": "Do not use the package's I1/EX/CX or the raw C from a format error as a valid new assessment, and do not fill empty values with 0.",
      "criterion": "Preserve the current ?, empty value, and Caution, the original designations, the absence of calculations, and the boundary that this is not independent verification.",
      "basis": "M04 §4.5, §4.6.3; limits on the current data transformation reflect the user-defined scope and internal design; Chamgap's own independence and attribution criteria. The official methods sections used in this pilot do not substantiate every detail of this item; M04 §4.6.3, M15 §15.3.1–15.3.3; the separation of statuses was internally designed",
      "condition_origin": "Individual criterion design and model review for a development case whose current retained content is known. These are not clinical preregistration or independent-validation criteria.",
      "proposed_research": "If new direct evidence is actually acquired, handle any update to the original assessment under separate authorization, versioning, and evidence review; this transformation table only links the original content and change events.",
      "current_reports": [],
      "existence": "Linked claims/results and limitations exist in the current retained summary. This is not current verification of external existence or of all studies.",
      "acquired_read": "Summary read: the current Korean/structured stored summary and the relevant locations were actually read. External clinical/official original texts were not read this time.",
      "observation": "The current grade ?, empty score, and safety Caution are maintained. Eligible effect, SE, CI, P, and n remain empty values, and no calculation is performed in this work. Distinguish the unassigned current axes from the package's I1/EX/CX and the raw C resulting from the calculator's format error. Completion of a technical transformation is not independent clinical/methodological certification.",
      "condition_status": "Met",
      "status_reason": "The boundaries between the original assessment, historical designations, current unverified information, and absence of new calculations are preserved. This does not mean that recurrence efficacy has been established.",
      "missingness": "Effect direction, magnitude, precision, and eligible comparative evidence remain unverified.",
      "uncertainty": "Effect direction, magnitude, precision, and eligible comparative evidence remain unverified.",
      "review_date": "2026-10-05",
      "reading_status": "Original source not read · Stored summary read",
      "additional_material": "Original records of current grade/score, axes, primary_result, historical package/calculations, and editorial decisions"
    }
  ],
  "reports": [
    {
      "report_id": "S01",
      "title": "Noureldin et al. Is it safe to prescribe ascorbic acid for urinary acidification in stone-forming patients with alkaline urine? Turk J Urol 2017;43:183–188.",
      "url": "https://urologyresearchandpractice.org/index.php/pub/article/view/2967/2963",
      "report_type": "Retrospective exposure-group report involving mixed stones and alkaline urine",
      "existence": "Retained identity, results, and limitations are recorded in the current sources/citations. This is not new verification of current external existence, publication, or public availability.",
      "acquired_read": "Summary read: the corresponding bibliography, extraction, limitations, and historical access in the currently stored manuscript were read. The external original material was not read in this work.",
      "study_family": "F01",
      "independent_replication": null,
      "observed_result": "There were 43 people identified and 24 included, with a mean age of 60.6 years (95% CI 52.7–68.5); 11/24 were women. The median dose was 1,000 mg/day (range 500–2,000), median follow-up was 22.6 months (range 19.7–32.1), and 8/24 people experienced the composite event of growth/progression of existing stones or new stones. Among the 17 with baseline composition verified, 2 had calcium-oxalate stones; a 0 in the calcium-oxalate cell among the 3 with follow-up composition does not mean 0 recurrences among the 24 people. Urinary pH was the main outcome, and hyperoxaluria led to 1 discontinuation and 1 dose reduction.",
      "result_level": "Noncomparative composite events and safety context in mixed stones; not the target direct comparison; within the scope of the retained 2026-09-16 record, not direct verification of original clinical material in this work",
      "source_evidence_date": "2026-09-16",
      "materials": [
        {
          "material_type": "Full-text article",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S01-M1",
          "url": "https://urologyresearchandpractice.org/index.php/pub/article/view/2967/2963",
          "parent_url": "https://urologyresearchandpractice.org/index.php/pub/article/view/2967/2963"
        },
        {
          "material_type": "Study protocol and raw analysis data",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S01-M2",
          "url": null,
          "parent_url": "https://urologyresearchandpractice.org/index.php/pub/article/view/2967/2963"
        }
      ],
      "links": [
        {
          "label": "Source",
          "url": "https://urologyresearchandpractice.org/index.php/pub/article/view/2967/2963"
        }
      ]
    },
    {
      "report_id": "S02",
      "title": "Traxer et al. Effect of ascorbic acid consumption on urinary stone risk factors. J Urol 2003;170:397–401.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/12853784/",
      "report_type": "Randomized placebo-controlled crossover metabolic trial",
      "existence": "Retained identity, results, and limitations are recorded in the current sources/citations. This is not new verification of current external existence, publication, or public availability.",
      "acquired_read": "Summary read: the corresponding bibliography, extraction, limitations, and historical access in the currently stored manuscript were read. The external original material was not read in this work.",
      "study_family": "F02",
      "independent_replication": null,
      "observed_result": "In 12 calcium-oxalate stone formers and 12 nonformers, 1 g twice daily was compared with a matching placebo during two 6-day periods. Urinary oxalate in stone formers during the final 2 days of each period was 41.0 mg versus 30.5 mg, P < 0.001. The authors' description of a 33% increase is preserved as originally reported, with no recalculation in this work. Crossover sequence/washout, paired variance, and recurrence results are unverified.",
      "result_level": "Short-term urinary oxalate comparison; not symptomatic recurrence; within the scope of the retained 2026-09-16 record, not direct verification of original clinical material in this work",
      "source_evidence_date": "2026-09-16",
      "materials": [
        {
          "material_type": "Article abstract and bibliographic information",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S02-M1",
          "url": "https://pubmed.ncbi.nlm.nih.gov/12853784/",
          "parent_url": "https://pubmed.ncbi.nlm.nih.gov/12853784/"
        },
        {
          "material_type": "Full-text article",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S02-M2",
          "url": null,
          "parent_url": "https://pubmed.ncbi.nlm.nih.gov/12853784/"
        }
      ],
      "links": [
        {
          "label": "Source",
          "url": "https://pubmed.ncbi.nlm.nih.gov/12853784/"
        }
      ]
    },
    {
      "report_id": "S03",
      "title": "Baxmann et al. Effect of vitamin C supplements on urinary oxalate and pH in calcium stone-forming patients. Kidney Int 2003;63:1066–1071.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/12631089/",
      "report_type": "3-day before–after metabolic study",
      "existence": "Retained identity, results, and limitations are recorded in the current sources/citations. This is not new verification of current external existence, publication, or public availability.",
      "acquired_read": "Summary read: the corresponding bibliography, extraction, limitations, and historical access in the currently stored manuscript were read. The external original material was not read in this work.",
      "study_family": "F03",
      "independent_replication": null,
      "observed_result": "Among 47 adult calcium stone formers, 23 received 1 g/day and 24 received 2 g/day for 3 days; 20 healthy participants received 1 g/day. These are before–after data on urinary oxalate, pH, and the Tiselius index, and the healthy participants are not recurrence comparators for patients with prior stones. The stone-former population has not been verified as consisting entirely of calcium-oxalate stones, and clinical recurrence remains unverified.",
      "result_level": "Before–after urinary measures in calcium stone formers/healthy participants; composition and directness for recurrence unverified; within the scope of the retained 2026-09-16 record, not direct verification of original clinical material in this work",
      "source_evidence_date": "2026-09-16",
      "materials": [
        {
          "material_type": "Article abstract and bibliographic information",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S03-M1",
          "url": "https://pubmed.ncbi.nlm.nih.gov/12631089/",
          "parent_url": "https://pubmed.ncbi.nlm.nih.gov/12631089/"
        },
        {
          "material_type": "Full-text article",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S03-M2",
          "url": null,
          "parent_url": "https://pubmed.ncbi.nlm.nih.gov/12631089/"
        }
      ],
      "links": [
        {
          "label": "Source",
          "url": "https://pubmed.ncbi.nlm.nih.gov/12631089/"
        }
      ]
    },
    {
      "report_id": "S04",
      "title": "Massey et al. Ascorbate increases human oxaluria and kidney stone risk. J Nutr 2005;135:1673–1677.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/15987848/",
      "report_type": "Index and bibliographic information for an original metabolic study",
      "existence": "Retained identity, results, and limitations are recorded in the current sources/citations. This is not new verification of current external existence, publication, or public availability.",
      "acquired_read": "Summary read: the corresponding bibliography, extraction, limitations, and historical access in the currently stored manuscript were read. The external original material was not read in this work.",
      "study_family": "F04",
      "independent_replication": null,
      "observed_result": "Title and bibliographic leads are retained, but detailed N, dose, recurrence, and funding were not verified. Possible participant overlap with S17 Chai 2004 remains unresolved; they are kept in a conservative single F04 cluster and are not counted as independent replication.",
      "result_level": "F04 cluster with only metadata acquired; overlap with S17 unresolved; within the scope of the retained 2026-09-16 record, not direct verification of original clinical material in this work",
      "source_evidence_date": "2026-09-16",
      "materials": [
        {
          "material_type": "Article index and bibliographic information",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S04-M1",
          "url": "https://pubmed.ncbi.nlm.nih.gov/15987848/",
          "parent_url": "https://pubmed.ncbi.nlm.nih.gov/15987848/"
        },
        {
          "material_type": "Full-text article",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S04-M2",
          "url": null,
          "parent_url": "https://pubmed.ncbi.nlm.nih.gov/15987848/"
        }
      ],
      "links": [
        {
          "label": "Source",
          "url": "https://pubmed.ncbi.nlm.nih.gov/15987848/"
        }
      ]
    },
    {
      "report_id": "S05",
      "title": "Brundig et al. [Possibilities and limits in the treatment of cystine calculus diathesis with high-dose ascorbic acid. Results of a combined study with 17 patients]. Z Urol Nephrol 1986;79:137–146.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/3087087/",
      "report_type": "Translated abstract on high-dose treatment for cystine stones",
      "existence": "Retained identity, results, and limitations are recorded in the current sources/citations. This is not new verification of current external existence, publication, or public availability.",
      "acquired_read": "Summary read: the corresponding bibliography, extraction, limitations, and historical access in the currently stored manuscript were read. The external original material was not read in this work.",
      "study_family": "F05",
      "independent_replication": null,
      "observed_result": "The report concerns 17 people with cystine stones receiving 5 g/day; recurrence remained unchanged in 5 people, requiring another strategy. The 2 people with spontaneous passage are not a recurrence numerator. The 3 gastritis-related discontinuations are retained, along with pediatric indexing and unverified adult-only denominator, duration, and matched comparator information.",
      "result_level": "Recurrence/discontinuation context limited by different composition, age/duration, and comparison; within the scope of the retained 2026-09-16 record, not direct verification of original clinical material in this work",
      "source_evidence_date": "2026-09-16",
      "materials": [
        {
          "material_type": "Translated article abstract and bibliographic information",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S05-M1",
          "url": "https://pubmed.ncbi.nlm.nih.gov/3087087/",
          "parent_url": "https://pubmed.ncbi.nlm.nih.gov/3087087/"
        },
        {
          "material_type": "Full-text article",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S05-M2",
          "url": null,
          "parent_url": "https://pubmed.ncbi.nlm.nih.gov/3087087/"
        }
      ],
      "links": [
        {
          "label": "Source",
          "url": "https://pubmed.ncbi.nlm.nih.gov/3087087/"
        }
      ]
    },
    {
      "report_id": "S06",
      "title": "Lux and May. Long-term observation of young cystinuric patients under ascorbic acid therapy. Urol Int 1983;38:91–94.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/6845567/",
      "report_type": "Favorable indexed abstract on a small cystine series",
      "existence": "Retained identity, results, and limitations are recorded in the current sources/citations. This is not new verification of current external existence, publication, or public availability.",
      "acquired_read": "Summary read: the corresponding bibliography, extraction, limitations, and historical access in the currently stored manuscript were read. The external original material was not read in this work.",
      "study_family": "F06",
      "independent_replication": null,
      "observed_result": "A retained excerpt describes favorable ascorbic acid monotherapy in 4 young patients with cystinuria. Exact ages, doses, events/denominators, comparators, follow-up, and the original full text remain unverified.",
      "result_level": "Favorable course in 4 young patients; target eligibility unverified; within the scope of the retained 2026-09-16 record, not direct verification of original clinical material in this work",
      "source_evidence_date": "2026-09-16",
      "materials": [
        {
          "material_type": "Indexed article abstract excerpt",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S06-M1",
          "url": "https://pubmed.ncbi.nlm.nih.gov/6845567/",
          "parent_url": "https://pubmed.ncbi.nlm.nih.gov/6845567/"
        },
        {
          "material_type": "Full-text article",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S06-M2",
          "url": null,
          "parent_url": "https://pubmed.ncbi.nlm.nih.gov/6845567/"
        }
      ],
      "links": [
        {
          "label": "Source",
          "url": "https://pubmed.ncbi.nlm.nih.gov/6845567/"
        }
      ]
    },
    {
      "report_id": "S07",
      "title": "Asper and Schmucki. Cystinurietherapie mit Ascorbinsäure. Urol Int 1982;37:91–109.",
      "url": "https://karger.com/uin/article-abstract/37/2/91/303196/Cystinurietherapie-mit-Ascorbinsaure?redirectedFrom=PDF",
      "report_type": "Publisher abstract on urinary cystine outcomes",
      "existence": "Retained identity, results, and limitations are recorded in the current sources/citations. This is not new verification of current external existence, publication, or public availability.",
      "acquired_read": "Summary read: the corresponding bibliography, extraction, limitations, and historical access in the currently stored manuscript were read. The external original material was not read in this work.",
      "study_family": "F07",
      "independent_replication": null,
      "observed_result": "Favorable urinary cystine results are reported in 31 people with cystinuria receiving 5 g/day. Controlled longitudinal recurrence was not verified, and the digitization date is not counted as a new study in 2010.",
      "result_level": "Favorable urinary measures and original 1982 publication identity; not clinical recurrence; within the scope of the retained 2026-09-16 record, not direct verification of original clinical material in this work",
      "source_evidence_date": "2026-09-16",
      "materials": [
        {
          "material_type": "Publisher article abstract",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S07-M1",
          "url": "https://karger.com/uin/article-abstract/37/2/91/303196/Cystinurietherapie-mit-Ascorbinsaure?redirectedFrom=PDF",
          "parent_url": "https://karger.com/uin/article-abstract/37/2/91/303196/Cystinurietherapie-mit-Ascorbinsaure?redirectedFrom=PDF"
        },
        {
          "material_type": "Full-text article",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S07-M2",
          "url": null,
          "parent_url": "https://karger.com/uin/article-abstract/37/2/91/303196/Cystinurietherapie-mit-Ascorbinsaure?redirectedFrom=PDF"
        }
      ],
      "links": [
        {
          "label": "Source",
          "url": "https://karger.com/uin/article-abstract/37/2/91/303196/Cystinurietherapie-mit-Ascorbinsaure?redirectedFrom=PDF"
        }
      ]
    },
    {
      "report_id": "S08",
      "title": "Ferraro et al. Total, Dietary, and Supplemental Vitamin C Intake and Risk of Incident Kidney Stones. Am J Kidney Dis 2016;67:400–407.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/26463139/",
      "report_type": "Prospective cohort analysis of first-stone occurrence",
      "existence": "Retained identity, results, and limitations are recorded in the current sources/citations. This is not new verification of current external existence, publication, or public availability.",
      "acquired_read": "Summary read: the corresponding bibliography, extraction, limitations, and historical access in the currently stored manuscript were read. The external original material was not read in this work.",
      "study_family": "F08",
      "independent_replication": null,
      "observed_result": "There were 156,735 women, 40,536 men, 6,245 first stones, and median follow-up of 11.3–11.7 years. In men, supplementation ≥ 1,000 mg/day versus no supplementation had an adjusted HR of 1.19 (95% CI 1.01–1.40), with a trend P = 0.001; the abstract did not report an association in women. Dietary C and supplemental exposure are separated, and cohort reuse and the distinction between first occurrence and recurrence are retained.",
      "result_level": "Observational association with first occurrence in the general population, by sex/supplemental exposure; not recurrence causation; within the scope of the retained 2026-09-16 record, not direct verification of original clinical material in this work",
      "source_evidence_date": "2026-09-16",
      "materials": [
        {
          "material_type": "Article abstract and figure captions",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S08-M1",
          "url": "https://pubmed.ncbi.nlm.nih.gov/26463139/",
          "parent_url": "https://pubmed.ncbi.nlm.nih.gov/26463139/"
        },
        {
          "material_type": "Full-text article",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S08-M2",
          "url": null,
          "parent_url": "https://pubmed.ncbi.nlm.nih.gov/26463139/"
        }
      ],
      "links": [
        {
          "label": "Source",
          "url": "https://pubmed.ncbi.nlm.nih.gov/26463139/"
        }
      ]
    },
    {
      "report_id": "S09",
      "title": "Yoshikawa et al. [Descriptive label: ascorbic acid during treatment of infected obstructing stones]. Urol Case Rep, online 2024.",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11699346/",
      "report_type": "Index and partial course of an acute dissolution case",
      "existence": "Retained identity, results, and limitations are recorded in the current sources/citations. This is not new verification of current external existence, publication, or public availability.",
      "acquired_read": "Summary read: the corresponding bibliography, extraction, limitations, and historical access in the currently stored manuscript were read. The external original material was not read in this work.",
      "study_family": "F09",
      "independent_replication": null,
      "observed_result": "Acute dissolution in 1 older man involved concurrent exposure to antibiotics, stenting, and ascorbic acid, with different exposure after discharge. Composition was inferred, and these are not quantitative recurrence-efficacy data. The title is a descriptive label rather than a transcription of the exact original title.",
      "result_level": "Concomitant antibiotics/stenting, inferred composition, and a single person; not recurrence prevention; within the scope of the retained 2026-09-16 record, not direct verification of original clinical material in this work",
      "source_evidence_date": "2026-09-16",
      "materials": [
        {
          "material_type": "Case-report index and partial clinical course",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S09-M1",
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11699346/",
          "parent_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11699346/"
        },
        {
          "material_type": "Full-text article",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S09-M2",
          "url": null,
          "parent_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11699346/"
        }
      ],
      "links": [
        {
          "label": "Source",
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11699346/"
        }
      ]
    },
    {
      "report_id": "S10",
      "title": "Mori et al. Clinical study on cystinuria. Jpn J Urol 1986;77:1559–1565.",
      "url": "https://www.jstage.jst.go.jp/article/jpnjurol1928/77/10/77_10_1559/_article/-char/en",
      "report_type": "Original abstract and partial page on cystine treatment",
      "existence": "Retained identity, results, and limitations are recorded in the current sources/citations. This is not new verification of current external existence, publication, or public availability.",
      "acquired_read": "Summary read: the corresponding bibliography, extraction, limitations, and historical access in the currently stored manuscript were read. The external original material was not read in this work.",
      "study_family": "F10",
      "independent_replication": null,
      "observed_result": "A discussion of several treatments for cystinuria and the original abstract/partial page p.1563 are historically retained. A controlled recurrence comparison of vitamin C alone is unverified, and other treatments or cited articles are not counted as new C recurrence data.",
      "result_level": "Discussion of several treatments and partial verification of p.1563; C-alone recurrence comparison unverified; within the scope of the retained 2026-09-16 record, not direct verification of original clinical material in this work",
      "source_evidence_date": "2026-09-16",
      "materials": [
        {
          "material_type": "Article abstract and partial page",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S10-M1",
          "url": "https://www.jstage.jst.go.jp/article/jpnjurol1928/77/10/77_10_1559/_article/-char/en",
          "parent_url": "https://www.jstage.jst.go.jp/article/jpnjurol1928/77/10/77_10_1559/_article/-char/en"
        },
        {
          "material_type": "Full-text article",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S10-M2",
          "url": null,
          "parent_url": "https://www.jstage.jst.go.jp/article/jpnjurol1928/77/10/77_10_1559/_article/-char/en"
        }
      ],
      "links": [
        {
          "label": "Source",
          "url": "https://www.jstage.jst.go.jp/article/jpnjurol1928/77/10/77_10_1559/_article/-char/en"
        }
      ]
    },
    {
      "report_id": "S11",
      "title": "Farkouh et al. The Effect of Vitamin C Supplements on Urinary Stone Risk. Online July 31, 2026.",
      "url": "https://journals.sagepub.com/doi/10.1177/08927790261471733",
      "report_type": "Urinary-risk review abstract and citation map",
      "existence": "Retained identity, results, and limitations are recorded in the current sources/citations. This is not new verification of current external existence, publication, or public availability.",
      "acquired_read": "Summary read: the corresponding bibliography, extraction, limitations, and historical access in the currently stored manuscript were read. The external original material was not read in this work.",
      "study_family": null,
      "independent_replication": null,
      "observed_result": "This is an evidence map from a review used to locate intervention studies on urinary risk. The online date, 2026-07-31, precedes the cutoff date, but the search ended earlier and does not establish current exhaustive acquisition of studies. It is not counted as a new comparative trial, unique participants, or replication independent in funding.",
      "result_level": "Mapping role of the 2026-07-31 review; not a new recurrence trial; within the scope of the retained 2026-09-16 record, not direct verification of original clinical material in this work",
      "source_evidence_date": "2026-09-16",
      "materials": [
        {
          "material_type": "Review article abstract and reference list",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S11-M1",
          "url": "https://journals.sagepub.com/doi/10.1177/08927790261471733",
          "parent_url": "https://journals.sagepub.com/doi/10.1177/08927790261471733"
        },
        {
          "material_type": "Full-text article",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S11-M2",
          "url": null,
          "parent_url": "https://journals.sagepub.com/doi/10.1177/08927790261471733"
        }
      ],
      "links": [
        {
          "label": "Source",
          "url": "https://journals.sagepub.com/doi/10.1177/08927790261471733"
        }
      ]
    },
    {
      "report_id": "S12",
      "title": "DailyMed. ASCOR (ascorbic acid injection), label revised July 2022.",
      "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=388aad52-fc01-4784-9791-1dbc80c69306",
      "report_type": "Official ASCOR intravenous injection label",
      "existence": "Retained identity, results, and limitations are recorded in the current sources/citations. This is not new verification of current external existence, publication, or public availability.",
      "acquired_read": "Summary read: the corresponding bibliography, extraction, limitations, and historical access in the currently stored manuscript were read. The external original material was not read in this work.",
      "study_family": null,
      "independent_replication": null,
      "observed_result": "The intravenous label contains risk contexts concerning oxalate nephropathy/stones, impaired renal function, dialysis, and prior oxalate stones, and a warning about high-dose/parenteral G6PD-related hemolysis. The buffered injectable preparation for short-term scurvy treatment differs from a pure oral preparation, and event rates or individual safety are not transferred to oral use.",
      "result_level": "Intravenous/high-dose warnings and a different formulation/indication; not oral risk rates; within the scope of the retained 2026-09-16 record, not direct verification of original clinical material in this work",
      "source_evidence_date": "2026-09-16",
      "materials": [
        {
          "material_type": "Full official web document",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S12-M1",
          "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=388aad52-fc01-4784-9791-1dbc80c69306",
          "parent_url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=388aad52-fc01-4784-9791-1dbc80c69306"
        }
      ],
      "links": [
        {
          "label": "Source",
          "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=388aad52-fc01-4784-9791-1dbc80c69306"
        }
      ]
    },
    {
      "report_id": "S13",
      "title": "NIH Office of Dietary Supplements. Vitamin C: Fact Sheet for Consumers.",
      "url": "https://ods.od.nih.gov/factsheets/VitaminC-Consumer/",
      "report_type": "Official NIH consumer web document",
      "existence": "Retained identity, results, and limitations are recorded in the current sources/citations. This is not new verification of current external existence, publication, or public availability.",
      "acquired_read": "Summary read: the corresponding bibliography, extraction, limitations, and historical access in the currently stored manuscript were read. The external original material was not read in this work.",
      "study_family": null,
      "independent_replication": null,
      "observed_result": "This records diarrhea, nausea, and abdominal pain with excessive intake, the adult upper limit of 2,000 mg/day from all sources combined, and iron overload in hemochromatosis. The upper limit is not an assurance of safety for stone patients. Historical reading of the consumer document is distinguished from failed access to the health-professional page.",
      "result_level": "General upper limit and gastrointestinal/iron context; not an assurance of safety for stone patients; within the scope of the retained 2026-09-16 record, not direct verification of original clinical material in this work",
      "source_evidence_date": "2026-09-16",
      "materials": [
        {
          "material_type": "Full official web document",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S13-M1",
          "url": "https://ods.od.nih.gov/factsheets/VitaminC-Consumer/",
          "parent_url": "https://ods.od.nih.gov/factsheets/VitaminC-Consumer/"
        }
      ],
      "links": [
        {
          "label": "Source",
          "url": "https://ods.od.nih.gov/factsheets/VitaminC-Consumer/"
        }
      ]
    },
    {
      "report_id": "S14",
      "title": "European Association of Urology. Urolithiasis: Metabolic Evaluation and Recurrence Prevention, accessed 2026-09-16.",
      "url": "https://uroweb.org/guidelines/urolithiasis/chapter/metabolic-evaluation-and-recurrence-prevention",
      "report_type": "Official EAU guideline web document",
      "existence": "Retained identity, results, and limitations are recorded in the current sources/citations. This is not new verification of current external existence, publication, or public availability.",
      "acquired_read": "Summary read: the corresponding bibliography, extraction, limitations, and historical access in the currently stored manuscript were read. The external original material was not read in this work.",
      "study_family": null,
      "independent_replication": null,
      "observed_result": "This advises calcium-oxalate stone formers to avoid excessive vitamin C and explains that its role in risk is controversial. It does not verify a quantitative randomized recurrence effect, risk rate, or safety threshold dose for a pure single-ingredient oral preparation.",
      "result_level": "Context of avoiding excessive intake and controversy; not a quantitative recurrence comparison; within the scope of the retained 2026-09-16 record, not direct verification of original clinical material in this work",
      "source_evidence_date": "2026-09-16",
      "materials": [
        {
          "material_type": "Full official web document",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S14-M1",
          "url": "https://uroweb.org/guidelines/urolithiasis/chapter/metabolic-evaluation-and-recurrence-prevention",
          "parent_url": "https://uroweb.org/guidelines/urolithiasis/chapter/metabolic-evaluation-and-recurrence-prevention"
        }
      ],
      "links": [
        {
          "label": "Source",
          "url": "https://uroweb.org/guidelines/urolithiasis/chapter/metabolic-evaluation-and-recurrence-prevention"
        }
      ]
    },
    {
      "report_id": "S15",
      "title": "ClinicalTrials.gov NCT06989320 registry lead.",
      "url": "https://clinicaltrials.gov/study/NCT06989320",
      "report_type": "Official trial-registration shell lead",
      "existence": "Retained identity, results, and limitations are recorded in the current sources/citations. This is not new verification of current external existence, publication, or public availability.",
      "acquired_read": "Summary read: the corresponding bibliography, extraction, limitations, and historical access in the currently stored manuscript were read. The external original material was not read in this work.",
      "study_family": null,
      "independent_replication": null,
      "observed_result": "Only the official registration shell was historically accessed; substantive fields, registration timing, and results for the endogenous-oxalate research lead are unverified. The existence of a URL/number is not presented as an eligible completed recurrence trial.",
      "result_level": "NCT06989320 identity lead; substantive registration/results unverified; within the scope of the retained 2026-09-16 record, not direct verification of original clinical material in this work",
      "source_evidence_date": "2026-09-16",
      "materials": [
        {
          "material_type": "Full official trial-registration web document",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S15-M1",
          "url": "https://clinicaltrials.gov/study/NCT06989320",
          "parent_url": "https://clinicaltrials.gov/study/NCT06989320"
        },
        {
          "material_type": "Official registration amendment history, protocol, and results documents",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S15-M2",
          "url": null,
          "parent_url": "https://clinicaltrials.gov/study/NCT06989320"
        }
      ],
      "links": [
        {
          "label": "Source",
          "url": "https://clinicaltrials.gov/study/NCT06989320"
        }
      ]
    },
    {
      "report_id": "S16",
      "title": "Registry mirror lead: Carbon-13 Ascorbic Acid oral load.",
      "url": "https://www.withpower.com/trial/phase-kidney-calculi-8-2021-ef6cd",
      "report_type": "3rd-party registration mirror lead",
      "existence": "Retained identity, results, and limitations are recorded in the current sources/citations. This is not new verification of current external existence, publication, or public availability.",
      "acquired_read": "Summary read: the corresponding bibliography, extraction, limitations, and historical access in the currently stored manuscript were read. The external original material was not read in this work.",
      "study_family": null,
      "independent_replication": null,
      "observed_result": "This is a 3rd-party mirror lead for Carbon-13 Ascorbic Acid oral loading. The linked metabolic lead was not adopted as a decisive result, and the official ID/version is unverified. It is not assumed to be the same trial as S15.",
      "result_level": "Discovery-level lead for Carbon-13 oral loading; official ID/version unverified; within the scope of the retained 2026-09-16 record, not direct verification of original clinical material in this work",
      "source_evidence_date": "2026-09-16",
      "materials": [
        {
          "material_type": "Full 3rd-party registration mirror web document",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S16-M1",
          "url": "https://www.withpower.com/trial/phase-kidney-calculi-8-2021-ef6cd",
          "parent_url": "https://www.withpower.com/trial/phase-kidney-calculi-8-2021-ef6cd"
        },
        {
          "material_type": "Full official trial-registration web document",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S16-M2",
          "url": null,
          "parent_url": "https://www.withpower.com/trial/phase-kidney-calculi-8-2021-ef6cd"
        }
      ],
      "links": [
        {
          "label": "Source",
          "url": "https://www.withpower.com/trial/phase-kidney-calculi-8-2021-ef6cd"
        }
      ]
    },
    {
      "report_id": "S17",
      "title": "Chai et al. Oxalate absorption and endogenous oxalate synthesis from ascorbate in calcium oxalate stone formers and non-stone formers. Am J Kidney Dis 2004;44:1060–1069.",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0272638604012636",
      "report_type": "Index and bibliographic information for an original metabolic study",
      "existence": "Retained identity, results, and limitations are recorded in the current sources/citations. This is not new verification of current external existence, publication, or public availability.",
      "acquired_read": "Summary read: the corresponding bibliography, extraction, limitations, and historical access in the currently stored manuscript were read. The external original material was not read in this work.",
      "study_family": "F04",
      "independent_replication": null,
      "observed_result": "The original publisher's title/bibliographic information is retained, but the DOI/PMID and detailed results are unverified, with empty values and an empty extraction preserved. Participant overlap with Massey 2005 remains unresolved, and this is not added as independent replication or new recurrence participants.",
      "result_level": "F04 cluster with detailed results not acquired and overlap with S04 unresolved; within the scope of the retained 2026-09-16 record, not direct verification of original clinical material in this work",
      "source_evidence_date": "2026-09-16",
      "materials": [
        {
          "material_type": "Article index and bibliographic information",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S17-M1",
          "url": "https://www.sciencedirect.com/science/article/abs/pii/S0272638604012636",
          "parent_url": "https://www.sciencedirect.com/science/article/abs/pii/S0272638604012636"
        },
        {
          "material_type": "Full-text article",
          "public_status": "Currently unverified (no external lookup)",
          "access_status": "Access not attempted",
          "acquired": false,
          "actually_read": "Not read",
          "as_of": "2026-10-05",
          "qualification": "Distinguish reading the currently stored summary and historical access from not reading the actual original material of the specified type in this work.",
          "material_id": "S17-M2",
          "url": null,
          "parent_url": "https://www.sciencedirect.com/science/article/abs/pii/S0272638604012636"
        }
      ],
      "links": [
        {
          "label": "Source",
          "url": "https://www.sciencedirect.com/science/article/abs/pii/S0272638604012636"
        }
      ]
    }
  ],
  "method_sources": [
    {
      "id": "M03",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2023-08",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-03",
      "section": "§3.1, §3.2.1–3.2.3, MECIR C5/C7/C13",
      "official_principle": "Clearly record the question, eligibility criteria and reasons for changes, and distinguish variations in the intervention.",
      "review_level": "Historical reuse of the actual retained HTML copy and SHA from 1585 and the methodological principles from that time. This is not new reading of the methods full text, a formal application, or clinical certification in this work."
    },
    {
      "id": "M04",
      "version": "Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-04",
      "section": "§4.5, §4.6.1–4.6.3, MECIR C42",
      "official_principle": "Distinguish and link studies and reports, and do not omit a study solely because its outcomes are not reported.",
      "review_level": "Historical reuse of the actual retained HTML copy and SHA from 1585 and the methodological principles from that time. This is not new reading of the methods full text, a formal application, or clinical certification in this work."
    },
    {
      "id": "M08",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2019-10",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08",
      "section": "§8.1–8.2.3, Table 8.2.a",
      "official_principle": "Hold the outcome and effect of interest fixed, then assess randomization, deviations, missing data, measurement and selective reporting.",
      "review_level": "Historical reuse of the actual retained HTML copy and SHA from 1585 and the methodological principles from that time. This is not new reading of the methods full text, a formal application, or clinical certification in this work."
    },
    {
      "id": "M15",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2023-08",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-15",
      "section": "§15.2.4, §15.3.1–15.3.3",
      "official_principle": "Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.",
      "review_level": "Historical reuse of the actual retained HTML copy and SHA from 1585 and the methodological principles from that time. This is not new reading of the methods full text, a formal application, or clinical certification in this work."
    },
    {
      "id": "M19",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2019-10",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-19",
      "section": "§19.1.2, §19.2.1–19.2.4",
      "official_principle": "Questions about harms may require designs, populations and follow-up different from efficacy questions. Case reports do not establish incidence.",
      "review_level": "Historical reuse of the actual retained HTML copy and SHA from 1585 and the methodological principles from that time. This is not new reading of the methods full text, a formal application, or clinical certification in this work."
    }
  ],
  "status_dictionary": {
    "Met": "Verification of the relevant retained/question condition; not confirmation of a clinical effect",
    "Unverified": "Required direct material/values are not verified within the current scope",
    "Conflicting information": "Used when an actual conflict concerning the same material/value is linked",
    "Not met": "Used when the required condition does not match what was actually verified",
    "Not applicable": "Used when a condition is not imposed on the particular question",
    "Not read": "The external original material was not actually read in this work",
    "Access failed": "Used only when an actual access failure occurred in this work",
    "Partly verified": "Some verified content coexists with gaps in applicability or data"
  },
  "study_overlap": {
    "state": "These are report links from the stored manuscript. F01 (S01): {\"study_id\": \"F01\", \"Linked source list\": [\"S01\"], \"design\": \"retrospective uncontrolled recurrence-related series\", \"selection\": \"excluded: comparator/composition/endpoint mismatch\", \"overlap_audit\": \"One original article across publisher/PMC/PubMed; not three studies.\", \"eligible_recurrence_participants_counted\": 0, \"trial_count_for_grade\": 0} · Retained families and eligibility/exclusion/overlap scope; not a new sum of independent trials or unique participants / F02 (S02): {\"study_id\": \"F02\", \"Linked source list\": [\"S02\"], \"design\": \"randomized placebo crossover, metabolic endpoints\", \"selection\": \"excluded: no recurrence result\", \"overlap_audit\": \"Preminger PMID 12853785 is commentary, not another trial.\", \"eligible_recurrence_participants_counted\": 0, \"trial_count_for_grade\": 0} · Retained families and eligibility/exclusion/overlap scope; not a new sum of independent trials or unique participants / F03 (S03): {\"study_id\": \"F03\", \"Linked source list\": [\"S03\"], \"design\": \"three-day before/after metabolic study\", \"selection\": \"excluded: surrogate and no matching event comparator\", \"overlap_audit\": \"No reuse of its 47 patients as a recurrence trial.\", \"eligible_recurrence_participants_counted\": 0, \"trial_count_for_grade\": 0} · Retained families and eligibility/exclusion/overlap scope; not a new sum of independent trials or unique participants / F04 (S04, S17): {\"study_id\": \"F04\", \"Linked source list\": [\"S04\", \"S17\"], \"design\": \"metabolic-study publication cluster, details partly inaccessible\", \"selection\": \"not decisive; no verified recurrence result\", \"overlap_audit\": \"Possible Chai/Massey participant overlap unresolved; conservative single cluster, not assumed proven identity.\", \"eligible_recurrence_participants_counted\": 0, \"trial_count_for_grade\": 0} · Retained families and eligibility/exclusion/overlap scope; not a new sum of independent trials or unique participants / F05 (S05): {\"study_id\": \"F05\", \"Linked source list\": [\"S05\"], \"design\": \"cystine stone treatment series\", \"selection\": \"excluded: composition, age, comparator and endpoint-definition limitations\", \"overlap_audit\": \"No linkage to other cystinuria series established; not pooled.\", \"eligible_recurrence_participants_counted\": 0, \"trial_count_for_grade\": 0} · Retained families and eligibility/exclusion/overlap scope; not a new sum of independent trials or unique participants / F06 (S06): {\"study_id\": \"F06\", \"Linked source list\": [\"S06\"], \"design\": \"small favorable cystinuria series\", \"selection\": \"excluded; detailed eligibility inaccessible\", \"overlap_audit\": \"No independence or participant overlap asserted.\", \"eligible_recurrence_participants_counted\": 0, \"trial_count_for_grade\": 0} · Retained families and eligibility/exclusion/overlap scope; not a new sum of independent trials or unique participants / F07 (S07): {\"study_id\": \"F07\", \"Linked source list\": [\"S07\"], \"design\": \"cystinuria metabolic report\", \"selection\": \"excluded: urinary endpoint and wrong composition\", \"overlap_audit\": \"Earlier descriptions cited elsewhere are not counted as replication.\", \"eligible_recurrence_participants_counted\": 0, \"trial_count_for_grade\": 0} · Retained families and eligibility/exclusion/overlap scope; not a new sum of independent trials or unique participants / F08 (S08): {\"study_id\": \"F08\", \"Linked source list\": [\"S08\"], \"design\": \"three prospective incident-stone cohorts\", \"selection\": \"excluded: incidence, not verified prior-stone recurrence; observational association only\", \"overlap_audit\": \"NHS I, NHS II, HPFS; earlier publications may reuse cohorts. Never add populations across reports.\", \"eligible_recurrence_participants_counted\": 0, \"trial_count_for_grade\": 0} · Retained families and eligibility/exclusion/overlap scope; not a new sum of independent trials or unique participants / F09 (S09): {\"study_id\": \"F09\", \"Linked source list\": [\"S09\"], \"design\": \"acute dissolution case report\", \"selection\": \"excluded: dissolution, cointerventions, composition uncertainty\", \"overlap_audit\": \"One person, not longitudinal comparative recurrence prevention.\", \"eligible_recurrence_participants_counted\": 0, \"trial_count_for_grade\": 0} · Retained families and eligibility/exclusion/overlap scope; not a new sum of independent trials or unique participants / F10 (S10): {\"study_id\": \"F10\", \"Linked source list\": [\"S10\"], \"design\": \"cystinuria series/reviewed treatments\", \"selection\": \"excluded: vitamin-C-specific comparator not verified\", \"overlap_audit\": \"Cited vitamin-C papers mapped to their own families, not new data.\", \"eligible_recurrence_participants_counted\": 0, \"trial_count_for_grade\": 0} · Retained families and eligibility/exclusion/overlap scope; not a new sum of independent trials or unique participants. The total number of unique trials and the total number of participants are unverified. Verification of the retained summaries is distinguished from not reading the original materials in this work, and report/family labels are not summed as total trials or participants.",
    "unique_trial_count": null,
    "unique_participant_count": null,
    "reason": "These are report links from the stored manuscript. F01 (S01): {\"study_id\": \"F01\", \"Linked source list\": [\"S01\"], \"design\": \"retrospective uncontrolled recurrence-related series\", \"selection\": \"excluded: comparator/composition/endpoint mismatch\", \"overlap_audit\": \"One original article across publisher/PMC/PubMed; not three studies.\", \"eligible_recurrence_participants_counted\": 0, \"trial_count_for_grade\": 0} · Retained families and eligibility/exclusion/overlap scope; not a new sum of independent trials or unique participants / F02 (S02): {\"study_id\": \"F02\", \"Linked source list\": [\"S02\"], \"design\": \"randomized placebo crossover, metabolic endpoints\", \"selection\": \"excluded: no recurrence result\", \"overlap_audit\": \"Preminger PMID 12853785 is commentary, not another trial.\", \"eligible_recurrence_participants_counted\": 0, \"trial_count_for_grade\": 0} · Retained families and eligibility/exclusion/overlap scope; not a new sum of independent trials or unique participants / F03 (S03): {\"study_id\": \"F03\", \"Linked source list\": [\"S03\"], \"design\": \"three-day before/after metabolic study\", \"selection\": \"excluded: surrogate and no matching event comparator\", \"overlap_audit\": \"No reuse of its 47 patients as a recurrence trial.\", \"eligible_recurrence_participants_counted\": 0, \"trial_count_for_grade\": 0} · Retained families and eligibility/exclusion/overlap scope; not a new sum of independent trials or unique participants / F04 (S04, S17): {\"study_id\": \"F04\", \"Linked source list\": [\"S04\", \"S17\"], \"design\": \"metabolic-study publication cluster, details partly inaccessible\", \"selection\": \"not decisive; no verified recurrence result\", \"overlap_audit\": \"Possible Chai/Massey participant overlap unresolved; conservative single cluster, not assumed proven identity.\", \"eligible_recurrence_participants_counted\": 0, \"trial_count_for_grade\": 0} · Retained families and eligibility/exclusion/overlap scope; not a new sum of independent trials or unique participants / F05 (S05): {\"study_id\": \"F05\", \"Linked source list\": [\"S05\"], \"design\": \"cystine stone treatment series\", \"selection\": \"excluded: composition, age, comparator and endpoint-definition limitations\", \"overlap_audit\": \"No linkage to other cystinuria series established; not pooled.\", \"eligible_recurrence_participants_counted\": 0, \"trial_count_for_grade\": 0} · Retained families and eligibility/exclusion/overlap scope; not a new sum of independent trials or unique participants / F06 (S06): {\"study_id\": \"F06\", \"Linked source list\": [\"S06\"], \"design\": \"small favorable cystinuria series\", \"selection\": \"excluded; detailed eligibility inaccessible\", \"overlap_audit\": \"No independence or participant overlap asserted.\", \"eligible_recurrence_participants_counted\": 0, \"trial_count_for_grade\": 0} · Retained families and eligibility/exclusion/overlap scope; not a new sum of independent trials or unique participants / F07 (S07): {\"study_id\": \"F07\", \"Linked source list\": [\"S07\"], \"design\": \"cystinuria metabolic report\", \"selection\": \"excluded: urinary endpoint and wrong composition\", \"overlap_audit\": \"Earlier descriptions cited elsewhere are not counted as replication.\", \"eligible_recurrence_participants_counted\": 0, \"trial_count_for_grade\": 0} · Retained families and eligibility/exclusion/overlap scope; not a new sum of independent trials or unique participants / F08 (S08): {\"study_id\": \"F08\", \"Linked source list\": [\"S08\"], \"design\": \"three prospective incident-stone cohorts\", \"selection\": \"excluded: incidence, not verified prior-stone recurrence; observational association only\", \"overlap_audit\": \"NHS I, NHS II, HPFS; earlier publications may reuse cohorts. Never add populations across reports.\", \"eligible_recurrence_participants_counted\": 0, \"trial_count_for_grade\": 0} · Retained families and eligibility/exclusion/overlap scope; not a new sum of independent trials or unique participants / F09 (S09): {\"study_id\": \"F09\", \"Linked source list\": [\"S09\"], \"design\": \"acute dissolution case report\", \"selection\": \"excluded: dissolution, cointerventions, composition uncertainty\", \"overlap_audit\": \"One person, not longitudinal comparative recurrence prevention.\", \"eligible_recurrence_participants_counted\": 0, \"trial_count_for_grade\": 0} · Retained families and eligibility/exclusion/overlap scope; not a new sum of independent trials or unique participants / F10 (S10): {\"study_id\": \"F10\", \"Linked source list\": [\"S10\"], \"design\": \"cystinuria series/reviewed treatments\", \"selection\": \"excluded: vitamin-C-specific comparator not verified\", \"overlap_audit\": \"Cited vitamin-C papers mapped to their own families, not new data.\", \"eligible_recurrence_participants_counted\": 0, \"trial_count_for_grade\": 0} · Retained families and eligibility/exclusion/overlap scope; not a new sum of independent trials or unique participants. The total number of unique trials and the total number of participants are unverified. Verification of the stored summaries is distinguished from not reading the original materials in this work, and report/family labels are not summed as total trials or participants."
  },
  "history": [
    {
      "date": "2026-11-06",
      "kind": "Separation of public-facing display and data",
      "view_version": "1.0",
      "change": "A public-facing display and data were prepared from the existing 41 items. No new clinical searches, changes to verification statuses, or scoring were performed."
    }
  ],
  "language": "en",
  "translation_date": "2026-11-06"
}